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A. actinomycetemcomitans Actinobacillus actinomycetemcomitans 
AL   attachment loss 
ALP   alkaline phosphatase 
α1-AT   alpha-1-antitrypsin 
α2-MG   alpha-2-macroglobulin 
AP   adult periodontitis 
AST   aspartate aminotransferase 
BANA   N-benzoyl-DL-arginine-2-naphthylamine 
B. forsythus  Bacteroides forsythus 
ß-G   beta-glucuronidase 
ß-NAH   beta-N-acetyl-hexosaminidase 
BI   bleeding index 
BM   basement membrane 
BOP   bleeding on probing 
Ca   calcium 
CAL   clinical attachment level 
CAM   cell adhesion molecule 
CA-MMP   cysteine array matrix metalloproteinase 
CPITN   community periodontal index of treatment needs 
C. pneumoniae  Chlamydia pneumoniae 
DNA   deoxyribonucleic acid 
ECM   extracellular matrix 
ELISA   enzyme-linked immunosorbent assay 
FcγR   Fc gamma receptor 
GAG   glycosaminoglycan 
GCF   gingival crevicular fluid 
GI   gingival index 
GPI   glycosylphosphatidylinositol 
HIV   human immunodeficiency virus 
HLA   human leukocyte antigen 
ICAM   intercellular adhesion molecule 
ICTP   pyridinoline cross-linked carboxyterminal telopeptide of type 
I collagen 
IFMA   time-resolved immunofluorometric assay 
Ig   immunoglobulin 
IL   interleukin 
IL-1ra   receptor antagonist of IL-1 
JE   junctional epithelium 
JP   juvenile periodontitis 
kDa   kilo Dalton 
LDD   low-dose doxycycline 
LJP   localised juvenile periodontitis 
LL-37   human cathelidicin peptide 
LPS   lipopolysaccharide 
MGI   modified gingival index 
MMP   matrix metalloproteinase 
MPO   myeloperoxidase 
MT-MMP   membrane-type MMP 
NS   non-smoker 
OC   osteocalcin 
OPN   osteopontin 
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PCR   polymerase chain reaction 
PGE2   prostaglandin-E2
PD   pocket probing depth 
P. gingivalis  Porphyromonas gingivalis 
PI   plaque index 
PISF   peri-implant sulcus fluid 
PMN   polymorphonuclear leukocyte, neutrophil leukocyte 
PST   Periodontal Susceptibility Test 
rRNA   ribosomal ribonucleic acid 
ROS   reactive oxygen species 
S   smoker 
sICAM-1   intercellular molecule-1 
SRP   scaling and root planing 
Supp   suppuration 
TNFα   tumour necrosis factor alpha 
TIMP   tissue inhibitor of metalloproteinases 
t-PA   tissue/blood vessel type plasminogen activator 
u-PA   urokinase type plasminogen activator 
VES   visual elastase scores 




Matrix metalloproteinase (MMP) -8, collagenase-2, is a key mediator of irreversible tissue 
destruction in chronic periodontitis and detectable in gingival crevicular fluid (GCF). MMP-8 
mostly originates from neutrophil leukocytes, the first line of defence cells which exist 
abundantly in GCF, especially in inflammation. MMP-8 is capable of degrading almost all 
extra-cellular matrix and basement membrane components and is especially efficient against 
type I collagen. Thus the expression of MMP-8 in GCF could be valuable in monitoring the 
activity of periodontitis and possibly offers a diagnostic means to predict progression of 
periodontitis. 
 
In this study the value of MMP-8 detection from GCF in monitoring of periodontal health 
and disease was evaluated with special reference to its ability to differentiate periodontal 
health and different disease states of the periodontium and to recognise the progression of 
periodontitis, i.e. active sites. For chair-side detection of MMP-8 from the GCF or peri-
implant sulcus fluid (PISF) samples, a dip-stick test based on immunochromatography 
involving two monoclonal antibodies was developed. 
 
The immunoassay for the detection of MMP-8 from GCF was found to be more suitable for 
monitoring of periodontitis than detection of GCF elastase concentration or activity. 
Periodontally healthy subjects and individuals suffering of gingivitis or of periodontitis could 
be differentiated by means of GCF MMP-8 levels and dipstick testing when the positive 
threshold value of the MMP-8 chair-side test was set at 1000 µg/l. MMP-8 dipstick test 
results from periodontally healthy and from subjects with gingivitis were mainly negative 
while periodontitis patients’ sites with deep pockets (> 5 mm) and which were bleeding on 
probing were most often test positive. Periodontitis patients’ GCF MMP-8 levels decreased 
with hygiene phase periodontal treatment (scaling and root planing, SRP) and even reduced 
during the three month maintenance phase. A decrease in GCF MMP-8 levels could be 
monitored with the MMP-8 test. Agreement between the test stick and the quantitative assay 
was very good (κ = 0.81) and the test provided a baseline sensitivity of 0.83 and specificity 
of 0.96. 
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During the 12-month longitudinal maintenance phase, periodontitis patients’ progressing 
sites (sites with an increase in attachment loss ≥ 2 mm during the maintenance phase) had 
elevated GCF MMP-8 levels compared with stable sites. General mean MMP-8 
concentrations in smokers’ (S) sites were lower than in non-smokers’ (NS) sites but in 
progressing S and NS sites concentrations were at an equal level. Sites with exceptionally 
and repeatedly elevated MMP-8 concentrations during the maintenance phase were clustered 
in smoking patients with poor response to SRP (refractory patients). These sites especially 
were identified by the MMP-8 test. 
 
Subgingival plaque samples from periodontitis patients’ deep periodontal pockets were 
examined by polymerase chain reaction (PCR) to find out if periodontal lesions may serve as 
a niche for Chlamydia pneumoniae. Findings were compared with the clinical periodontal 
parameters and GCF MMP-8 levels to determine the correlation with periodontal status. 
Traces of C. pneumoniae were identified from one periodontitis patient’s pooled subgingival 
plaque sample by means of PCR. After periodontal treatment (SRP) the sample was negative 
for C. pneumoniae. Clinical parameters or biomarkers (MMP-8) of the patient with the 
positive C. pneumoniae finding did not differ from other study patients. 
 
In this study it was concluded that MMP-8 concentrations in GCF of sites from periodontally 
healthy individuals, subjects with gingivitis or with periodontitis are at different levels. The 
cut-off value of the developed MMP-8 test is at an optimal level to differentiate between 
these conditions and can possibly be utilised in identification of individuals at the risk of the 
transition of gingivitis to periodontitis. In periodontitis patients, repeatedly elevated GCF 
MMP-8 concentrations may indicate sites at risk of progression of periodontitis as well as 
patients with poor response to conventional periodontal treatment (SRP). This can be 
monitored by MMP-8 testing. Despite the lower mean GCF MMP-8 concentrations in 
smokers, a fraction of smokers’ sites expressed very high MMP-8 concentrations together 
with enhanced periodontal activity and could be identified with MMP-8 specific chair-side 
test. 
 
Deep periodontal lesions may be niches for non-periodontopathogenic micro-organisms with 
systemic effects like C. pneumoniae and possibly play a role in the transmission from one 




Periodontal diseases are very common in all populations: nearly all dentate individuals suffer 
of gingivitis at some point of life. Also mild and moderate forms of chronic periodontitis are 
rather common (Sheiham 1997). However, severe forms of periodontitis with advanced 
tissue destruction (chronic periodontitis and aggressive forms of periodontitis) are rare 
worldwide (Albandar et al. 1999) as well as in European populations (Morris et al. 2001; 
Hugoson et al. 1995; Sheiham et al. 1986; Bourgeois et al. 1997). 
 
Periodontal diagnosis is commonly based on clinical and radiological examination. With 
these methods it is possible to find out the current inflammatory status or already existing 
loss of periodontal attachment. Estimation of known risk factors such as plaque accumulation 
and oral hygiene status, smoking and some systemic factors such as diabetes give further 
information about the individual susceptibility which is not equal in all individuals. Only a 
proportion of individuals and tooth sites with gingival inflammation develop irreversible 
periodontal tissue loss (Albandar 2002). However, the commonly used methods are not 
optimal in expressing the current activity of the periodontal disease though non-existing 
bleeding on probing has been regarded as a reliable parameter of periodontal stability (Lang 
et al. 1986). 
 
Periodontal tissue destruction is a consequence of the inflammatory reaction in a susceptible 
host initiated in response to bacterial colonisation forming a biofilm in the subgingival 
environment (McCulloch 1994a, b; Kinane 2000) and it is caused by host originating 
substances released by inflammatory cells and activated tissue cells. 
 
During last years there has been a great interest in finding a biomarker which could reliably 
reveal active and tissue destroying periodontal disease, in order to identify those individuals 
who are at the risk of the transition of chronic gingivitis into irreversibly tissue destructing 
periodontitis or which could give us information about the periodontal treatment response. 
The main interest has focused on gingival crevicular fluid (GCF) as a potential diagnostic 
fluid but also saliva and oral rinses have been studied. GCF has a special role in site specific 
diagnosis because of its origin is very near the collecting site. Host derived enzymes and their  
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inhibitors, inflammatory and immune markers, tissue-breakdown products and enzymes of 
bacterial origin have been determined from GCF samples in numerous biomarker studies. 
 
The ideal biomarker or combination of biomarkers should be an indicator of true tissue 
destruction, preferably in advance of the event. An easy to use chair-side diagnostic test for 
precise diagnostic purposes with good sensitivity and specificity would be ideal for clinical 
use. Enzymes of neutrophil origin are abundant in inflamed gingival pockets and may give 
information about ongoing destruction of periodontal attachment. These can be captured by 
means of GCF sampling for determination at a site specific level. 
 
Human matrix metalloproteinases (MMPs) are a group of structurally related but genetically 
distinct endopeptidase enzymes that have defined roles in several physiologic but also in 
pathologic processes. They have for example the capacity to degrade practically all 
extracellular matrix and basement membrane matrices and components (Birkedal-Hansen et 
al. 1993; Sorsa et al. 2004a). Matrix metalloproteinase-8 (MMP-8) is the major collagenase 
enzyme present in inflamed human gingival tissue (Sorsa et al. 1988; Ingman et al. 1994a; 
McCulloch 1994a, b; Kiili et al. 2002). MMP-8 is also responsible for collagenase activity in 
chronic periodontitis GCF (Lee et al. 1995a; Ingman et al. 1996; Golub et al. 1997). MMP-8 
is released from inflammatory cells in an inactive pro-form and is activated by different host- 
and microbe-derived factors at the site of inflammation. After periodontal treatment the 
amount of MMP-8 in GCF has been found to be reduced and mostly present in the latent 
form (Ingman et al. 1993). Thus MMP-8 is a potential biomarker of interest (Sorsa et al. 
2004a, b). 
 
The microbiota of the oral cavity and periodontal pockets is extremely complex. Periodontal 
pockets may serve as a niche for non-periodontopathogenic species and have a role as a 
possible reservoir for infective material in human to human contacts. Chlamydia pneumoniae 
has been shown to be most common of Chlamydias in humans causing harmless upper 
respiratory tract infections in systemically healthy individuals. Moreover, C. pneumoniae is 
known to cause 5—10% of cases of serious pneumonias and it is also the factor behind 
several diseases like obstructive pulmonary disease, asthma, atherosclerosis, reactive 
arthritis, and lung cancer (Saikku and Paavonen 2003). Although C. pneumoniae is not 
regarded as having a role in pathogenesis of periodontal diseases (Tran et al. 1997) it may 
contribute, for example by increasing the local host response process. 
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5 REVIEW OF THE LITERATURE 
 
5.1. STRUCTURE OF HEALTHY PERIODONTIUM 
 
Supporting tissues of the teeth, the periodontium, comprises: 1) the gingiva, 2) the 
periodontal ligament, 3) the root cementum, and 4) the alveolar bone which consists of the 
alveolar bone proper and the alveolar process which are continuous with each other. Normal 
gingival tissues form a protective barrier against infection and the frictional forces of 
mastication. In healthy periodontal tissues tissue degradation and repair are in balance and 
the periodontium maintains the structural and functional integrity. 
 
Type I collagen is the major type of collagen in mature gingival connective tissue. Also type 
III collagen is localised in periodontal connective tissue while type IV collagen is the main 
collagenous component of the basement membrane (Chavrier et al. 1984). Type I collagen 
which is organised in dense bundles, maintains the integrity of the connective tissue as well 
as provides a major substratum for the attachment of the connective tissue cells. 
 
The gingiva (attached, free marginal and interdental) may be regarded as a collar of 
masticatory mucosa around the teeth and it is attached to both teeth and alveolar processes. 
Structurally, the gingiva is composed of a densely collagenous lamina propria including the 
supra-alveolar fibres, blood and lymphatic vessels and nerves and two different kinds of 
epithelia: oral epithelium facing the oral cavity and sulcular epithelium facing the tooth 
(Schroeder and Listgarten 1997). On the contact surface between the tooth and the gingiva 
exists junctional epithelium (JE), a thin, non-keratinised epithelium with wide intercellular 
spaces which allow the inflammatory cells to migrate through the epithelium. The cells of the 
internal basal lamina of JE form the epithelial attachment to the tooth surface via 
hemidesmosomes. JE is a dynamic, constantly remodelling tissue with a high cellular 
turnover rate (Bosshardt and Lang 2005). 
 
Periodontal ligament, a fibre apparatus connecting the tooth to the alveolar bone, is a 
unique tissue; small in proportion but definitively functionally important. It has similarities 
with other tendons and ligaments but it is specific because it inter-connects two different kind 
of oral hard tissue: instead of having two bone insertions it enters the radicular cementum at  
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the tooth end. The periodontal ligament is not only a suspensory complex but also 
detrimental for mechanotransdunction of signals from teeth to alveolar bone when physical 
forces are applied and when there is a requirement for rapid remodelling of bone (McCulloch 
et al. 2000). The extracellular matrix of periodontal ligament is a loose plexus of wavy 
collagen fibrils which immerse in a highly hydrated interfibrillar matrix. The major type of 
collagen in the periodontal ligament, type I, is embedded in type III collagen with a 
secondary role in the fibrous supportive structures (Embery 1990). 
 
The main function of cementum is to attach the tooth to surrounding alveolar bone via the 
periodontal ligament. No physiologic resorption or remodelling occurs in cementum; instead 
a slow apposition of new cellular cementum continues throughout lifetime as a consequence 
of physiologic demands. 
 
Alveolar bone is the least stable of periodontal structures which may be one factor in the 
pathogenesis of periodontitis. The organisation of alveolar bone is extremely complex, 
influenced by masticatory stress and other oral factors. The turnover rate is high because of 
the factors mentioned above but in the healthy/normal state resorption and formation of new 
bone is in balance and regulated by local and systemic factors. 
 
5.2. DIFFERENT DISEASE STATES OF PERIODONTIUM 
 
5.2.1. Classification of periodontal diseases 
 
The latest classification of periodontal diseases is from the year 1999 (International 
Workshop for a Classification of Periodontal Diseases and Conditions 1999). It is mainly 
based on infection / host response paradigm (Armitage 2002), and all classification 
terminology dependent on age and rate of progression has been discarded (Armitage 1999). 
Categories I and II cover the most common periodontal diseases with the greatest prevalence: 
category I encompasses gingival diseases, and category II consists of chronic forms of 
periodontitis. Chronic periodontitis replaces the category adult periodontitis in the 1989 
classification. Chronic periodontitis, which is common in adults, can also be seen in 
adolescents (Armitage 1999). However, term “chronic” does not mean “incurable” (Armitage 
1999), and chronic periodontitis may be a constellation of diseases and not a single entity  
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(Armitage 2002). Aggressive periodontal diseases (localised and generalised) belong to 
category III which encompasses all highly destructive forms of periodontitis independent of 
the subject’s age (in children, without any detectable underlying systemic disease). This 
category covers all forms of periodontitis which were in the 1989 classification under the 
category: early-onset periodontitis (prepubertal, juvenile and rapidly progressive 
periodontitis) (The American Academy of Periodontology 1989). Other categories of the 
1999 classification are: periodontitis as a manifestation of systemic diseases (IV), necrotising 
periodontal diseases (V), abcesses of the periodontium (VI), periodontitis associated with 
endodontic lesions (VII), and developmental or acquired deformities and conditions (VIII). 
 
The present-day classification is not based on etiology or pathology of periodontal diseases 
which would demand more knowledge about the host-microbial interactions and the 
environmental factors behind them. Instead it reflects the current understanding of the nature 





Almost 100% of the population suffers periodically from gingivitis, a reversible 
inflammation of the gingiva. The main etiological factor behind gingival inflammation is the 
accumulation of a biofilm on the tooth surface when oral hygiene measures are insufficient. 
With increasing bacterial load typical signs of inflammation appear: redness, change of the 
surface structure with oedema, and bleeding even when slightly touched with a tooth brush or 
periodontal probe. When bacterial plaque accumulates on the tooth surface, a neutrophil-
dominated response starts, and in few days clinical signs of gingival inflammation can be 
seen with increased flow of gingival crevicular fluid (GCF). When causative factors (reasons 
for bacterial plaque accumulation, i.e. insufficient oral hygiene or iatrogenic factors) are 
eliminated, the gingival tissue returns to a healthy state (Løe et al. 1965). Though there is 
still no clinical means to recognise individual susceptibility for “dangerous” gingivitis with 
risk of progressing to periodontitis, there are known risk factors which should be considered 
when estimating the risk. 
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Even in a pristine state of periodontal health, an accumulation of neutrophil leucocytes is 
present in gingival connective tissue underneath the epithelium lining the gingival crevice. 
Inflammatory cells in the subepithelial portion of the lamina propria immediately under JE 
and inside it are part of normal homeostasis and an essential part of the defence system in 
this structure which is continuously challenged by microbes (Schroeder and Listgarten 1997). 
 
One of the earliest changes associated with the transition from health to gingivitis is the 
increased GCF level of the neutrophil chemoattractant interleukin (IL) -8 (Tonetti et al. 
1998). During this phase pocket epithelium forms epithelial pegs into the connective tissue, 
and the epithelial surface towards the connective tissue increases. Already, during early 
gingivitis, many collagen fibres in the gingiva are broken down. This makes space for 
extravasation of inflammatory cells and infiltration into the gingival connective tissue. 
 
The inflammatory cell infiltrate of early gingivitis mainly consists of neutrophils. During the 
pathogenic process towards established gingivitis the infiltrate is characterised by the 
increase in plasma cells (10—30% of inflammatory cell infiltration), and plasma cells 
become the dominant cell (> 50%) in periodontitis i.e. when alveolar bone is lost and JE is 
migrating in an apical direction (Kinane and Lindhe 2003). 
 
5.2.3. Chronic periodontitis 
 
Untreated chronic gingivitis can stay unchanged for long periods, and epidemiological data 
suggests that only a proportion of individuals and tooth sites with gingival inflammation 
develop irreversible periodontal tissue loss, periodontitis (Albandar 2002). In 
epidemiological studies the worldwide prevalence of severe periodontal disease has been 
found to be low (Albandar et al. 1999). Advanced periodontal disease with deep pocketing is 
reported to be rare also in European populations (Morris et al. 2001; Hugoson et al. 1995; 
Sheiham et al. 1986; Bourgeois et al. 1997). In European subjects mild gingival 
inflammation is common as well as many adults have mild to moderate periodontal 
attachment loss at some sites of dentition (Sheiham 1997). A national survey in the USA 
showed that chronic periodontitis among dentate persons aged ≥ 30-years and with six or 
more remaining teeth is altogether common: 3.1% suffered from advanced, 9.5% from 
moderate, and 21.8% from mild chronic periodontitis (Albandar et al. 1999). In a recent 
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Finnish large scale population study (National Public Health Institute 2004) where 
periodontal disease was defined as having at least one periodontal pocket ≥ 4 mm, 70% of 
men and 60% of women over 44-years-old fulfilled this criterion. This means that gum 
diseases are common among Finnish adult population. 
 
Typical for chronic periodontitis is a rather weak activity of subgingival bacteria, and host 
response where lymphocytes are the dominating cells. As a reaction to inflammation, normal 
periodontal tissue transforms to granulation tissue with large numbers of infiltrated plasma 
cells and attachment of the tooth is lost. Granulation tissue prevents invasion of micro-
organisms and their virulence factors into the surrounding tissue and there exists a balance 
between the host and subgingival microbiota with minimal risk of systemic spread of 
infection. It is still unknown if chronic periodontitis progresses as bursts in individual sites or 
throughout the dentition at the same time or if the progression is gradual. All these forms 
may be possible at different time periods in the same dentition. 
 
5.3. PATHOGENESIS OF PERIODONTITIS AND PERIODONTAL INFECTION 
 
In periodontitis, the gram-negative microbial plaque colonises into the deepened gingival 
crevice and evokes a chronic inflammatory response. The inflammatory cascade starts with 
the penetration of lipopolysaccharides (LPS) from the surface of gram-negative bacteria into 
periodontal tissues. LPS stimulates monocytes/macrophages to secrete modulators of 
inflammation, like prostaglandin E2 (PGE2), IL-1, -6 and -8, tumour necrosis factor alpha 
(TNFα), and collagenases (MMPs), which in turn activate vascular smooth muscle cells, 
fibroblasts, further monocytes/macrophages, and osteoclasts to produce various proteolytic 
enzymes and stimulate bone resorption (Figure 1). This leads to clinical inflammation and 
periodontal attachment loss. The hallmark in the progression of gingivitis to periodontitis is 
regarded to be the conversion of JE to pocket epithelium. The clinical sign is the formation of 
periodontal pockets. 
 
In addition to the role as a seal between the tooth and underlying tissues, JE participates in 
the host defence mechanisms and has an active role in the innate host defence (Bosshardt and 
Lang 2005). Periodontal pocket formation has been attributed to a loss of cell to cell contacts 
in the coronal portion of JE and the detachment of JE cells directly attached to the tooth 
 17
(DAT-cells) (Pöllänen et al. 2003). This focal disintegration of JE is further exacerbated by 
increased numbers of T- and B-lymphocytes, monocytes/macrophages and neutrophils 
(Schroeder and Listagarten 1997). Moreover, JE can be invaded by bacteria and bacterial 
products which can directly participate in the process of structural disintegration of JE 
(Bosshardt and Lang 2005). 
 
 
Figure 1. A microbial biofilm induces the host response. Activated macrophages induce vascular 
changes with increased vasopermeability. This leads to increased exudation and neutrophils are 
attracted to the site of inflammation. As a consequence of enzyme release by inflammatory cells, 
connective tissue as well as epithelial cells and basement membrane will be degraded (bystander 
damage). Osteoclasts will be activated to degrade alveolar bone. Some focal biomarkers of neutrophil 
and macrophage origin are shown. 
 
JE cells express numerous cell adhesion molecules (CAMs). The expression of intercellular 
adhesion molecule-1 (ICAM-1) forms a gradient which is thought to be a mechanism guiding 
neutrophils towards the bottom of the sulcus to counteract the bacterial challenge (Tonetti 
1997; Tonetti et al. 1998). JE expresses also IL-8, IL-1α, IL-1β, and TNFα especially in its 
coronal half (Miyauchi et al. 2001) and natural antibacterial peptides and proteins such as β- 
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defencins, LL-37 (human cathelidicin-derived peptide), and calprotectin in response to 
bacterial challenge (Dale 2002). The epithelium responds to bacteria also by signalling 
further host responses, by increasing proliferation, by changing differentiation and cell death, 
and it integrates innate and acquired immunity (Dale 2002). 
 
A variety of factors are thought to contribute to the pathogenesis of periodontitis including 
inadequate oral hygiene, systemic diseases, genetic predisposition and smoking habits, all of 
which modify the host response as well as the composition of the oral microbiota 
(McCulloch 1994a, b; Kinane 2000). In a susceptible host periodontal tissue destruction is a 
consequence of the inflammatory reactions initiated in response to bacterial colonisation 
forming the biofilm in the subgingival environment (McCulloch 1994a, b; Kinane 2000). 
 
Some gram-negative or opportunistic bacterial species identified in deep periodontal pockets 
by culture are regarded to be the primary causative microbial species for development of 
periodontitis. However, in all cases the relationship between periodontopathogenic cultivable 
bacterial species and periodontal disease is not unambiguous and the same species can be 
found from both diseased and healthy sites (Moore and Moore 1994; Socransky and Haffajee 
1994). Current knowledge of the diversity of oral microbial species questions the role of the 
small number of pathogens as the sole cause of periodontal diseases (Slots 2005). Earlier 
adopted non-specific and specific disease models have been superseded by the ecological 
plaque hypothesis which implies that periodontitis is caused by resident flora which may 
contain pathogenic species (Marsh 1994) and that the relationship of certain bacteria in the 
pathogenesis of periodontal diseases is rather ecological than specific. The shift in the 
proportions of species may be a consequence of the changed gingival environment (Newman 
1990). The complex periodontal microbiota differs in composition from site to site in the 
same subject and from subject to subject (Haffajee and Socransky 2005). 
 
Molecular methods have revealed a tremendous diversity of oral and periodontal flora. The 
number of different micro-organisms recognised in the oral cavity has more than doubled in 
number by using molecular methods compared with the number isolated by culture 
techniques. This finding requires evaluating anew which species participate in the 
pathogenesis of different oral diseases (Tanner and Izard 2005). Tanner and Izard (2005) 
suggested that the detection of disease-associated mediators of host tissues should be used in 
association with detecting selected species for the assessment of microbial pathogenity. 
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The possible role of viruses in the etiology and pathogenesis of periodontal diseases has 
recently been speculated and herpes viruses have been studied as putative 
periodontopathogens (Slots 2005). An apparent association between human cytomegalovirus 
and progressing periodontitis has been detected (Kamma et al. 2001a; Kubar et al. 2004). 
Periodontal inflammatory cells contain nucleic acid sequences originating from herpes 
viruses and periodontal inflammatory cells infected by herpes viruses can express increased 
levels of tissue-damaging cytokines and chemokines (Mogensen and Paludan 2001). 
 
The main immune defences against subgingival infection are neutrophil leukocytes 
(polymorphonuclear leukocytes, PMN), antibodies and complement, which work in concert. 
Antibodies and complement work synergistically in opsonising bacteria, and chemotaxis and 
phagocytosis by neutrophils becomes more effective. The abundance of released enzymes 
from neutrophils, other inflammatory cells and activated tissue cells cause damage to host 
tissue also i.e. bystander damage. 
 
5.3.1. The periodontal pocket as a niche for Chlamydia pneumoniae 
 
The oral microbiota consists of 500—600 species most of which have not been associated 
with the pathogenesis of periodontitis. However, periodontal pockets may harbour species 
which may be relevant for systemic health. 
 
Chlamydias are tiny gram-negative bacteria of which Chlamydia pneumoniae has been 
identified as a separate species in 1989. C. pneumoniae has been shown to be the most 
common Chlamydia in humans causing several diseases like obstructive pulmonary disease, 
asthma, atherosclerosis, reactive arthritis, and lung cancer (Saikku and Paavonen 2003). 
Nearly all individuals suffer from C. pneumoniae infection 2—3 times during their lifetime 
but in most cases the infection is a mild upper respiratory tract infection. However, C. 
pneumoniae is the factor behind 5—10% of cases of serious pneumonia which can be fierce 
and lead to death in patients with poor resistance (Saikku and Paavonen 2003). There is 
evidence that C. pneumoniae may play a role in chronic lung diseases as well as in 
atherosclerosis plaque formation (Mosorin et al. 2000; Corrado et al. 2005; Volanen et al. 
2006), in acute heart attack (Arcari et al. 2005), and in cardiac valvular disorders (Nyström-
Rosander et al. 2003; Skowasch et al. 2003). Chronic inflammation caused by C. 
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pneumoniae may even be the causative agent behind these disorders (Saikku and Paavonen 
2003). 
 
C. pneumoniae has been identified also in the oropharynx: during epidemics Chlamydia 
species have been found to be responsible for up to 9% of cases of pharyngitis in adults 
(Huovinen et al. 1989). C. pneumoniae is not regarded to have a role in the pathogenesis of 
periodontitis but deep periodontal pockets may be a niche for micro-organisms which are not 
regarded as periodontopathogenic bacteria such as C. pneumoniae. Thus periodontal pockets 
could be the reservoir of C. pneumoniae in otherwise symptomless carriers and a source of 
infection through transmission to more susceptible individuals. Tran et al. (1997), using a 
16S rRNA-based identification method, did not find C. pneumoniae in subgingival dental 
plaque samples from 50 adult patients with advanced periodontal disease thus concluding 
that C. pneumoniae is not part of the periodontopathogenic microbiota in humans. 
Interestingly, C. pneumoniae infection has lately been found with a nested polymerase chain 
reaction designed to identify C. pneumoniae DNA to be highly prevalent in cyclosporine-
induced post-transplant gingival overgrowth (Worm et al. 2004). 
 
5.4. SMOKING AS AN ETIOLOGICAL RISK FACTOR FOR PERIODONTITIS 
 
Smoking is a risk factor for the incidence and progression of periodontal disease (Bergström 
and Preber 1994; Grossi et al. 1994). From the data of a national survey in the USA it was 
estimated that in US adults with periodontitis, 41.9% cases were attributable to current 
smoking and 10.9% to former smoking (Tomar and Asma 2000). There is strong evidence 
suggesting an association between intensity and duration of smoking and periodontal 
attachment loss and severity of periodontitis (Grossi et al. 1995, 1997; Martinez-Canut et al. 
1995; Gonzales et al. 1996; Bergström et al. 2000). Smoking of one, 2—10 or 11—20 
cigarettes per day was associated with an increase in the prevalence of attachment loss of 
0.5%, 5% and 10%, respectively in a study of 889 periodontal patients (Martinez-Canut et al. 
1995). The number of smoking years has been shown to be associated with tooth loss and 
periodontitis irrespective of other environmental and behavioural factors (Jette et al. 1993) 
and smoking status is independently significantly related to the attachment level of teeth 
(Bergström et al. 2000; Bergström 2004). The effect is additive with increasing age (Haffajee 
and Socransky 2001a). However, there are also contradicting findings where smokers do not 
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have greater progression of periodontal disease as measured by pocket probing depth (PD) or 
attachment loss (AL) (Chen et al. 2001). 
 
Smoking impairs the normal defence mechanisms of the host response (Quinn et al. 1998; 
Mooney et al. 2001) and stimulates destructive effects of the host response (Gustafsson et al. 
2000; Persson et al. 2001). However, neither salivary nor GCF cotinine levels have been 
found to correlate significantly with PD, AL or tooth loss in smokers though mean GCF 
cotinine was about four times higher than mean salivary cotinine levels (Chen et al. 2001). 
 
The effect of smoking on periodontal health seems to be unrelated to the composition of the 
subgingival microflora (Preber et al. 1992; Stoltenberg et al. 1993; Darby et al. 2000; 
Boström et al. 2001). However, a difference between smoker (S) and non-smoker (NS) 
subjects’ subgingival microbiota has been found in the prevalence of species rather than 
counts or proportions of organisms (Haffajee and Socransky 2001b). There is also a finding 
with no statistical difference, in the occurrence of periodontopathogens (Actinobacillus 
actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia) (Boström et al. 
1998a). In smokers no microbial species is specifically associated with bleeding on probing 
(BOP) (Boström et al. 2001). 
 
The typical feature of smokers’ gingival tissue is keratinisation which may mask 
inflammation. Less BOP among smokers has been confirmed in several studies (Alavi et al. 
1995; Boström et al. 2001; Bergström and Boström 2001; Chen et al. 2001; Erdemir et al. 
2004) even in spite of a 2- to 3-fold greater disease severity measured as the number of deep 
periodontal pockets (Bergström and Boström 2001). The mechanism in smokers may be 
related rather to inflammation events than to vascular functions per se because periodontally 
healthy smokers and non-smokers do not differ regarding hemorrhagic responsiveness or 
vascular density (Bergström and Boström 2001). The effect of nicotine seems to be directed 
to vascular dynamics and cellular metabolism and it is not only due to vasoconstrictive action 
(Bergström and Boström 2001). In an experimental gingivitis study in healthy S and NS 
subjects Giannopoulou et al. (2003a) noted after a 10 day period of plaque accumulation 
significantly lower gingival index (GI) and less BOP in S than in NS subjects. 
 
There are also different or contradictory results where smokers demonstrated significantly 
more bleeding on probing (Renvert et al. 1998). Müller et al. (2002) observed in their 
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longitudinal study that smokers’ gingiva tended to convert to bleeding irrespective of 
presence of known risk factors for gingivitis in a gingivitis study investigating healthy young 
adults. However, in another study vasculature of gingival tissues between periodontally 
healthy smokers and non-smokers was not different (Persson and Bergström 1998). 
 
There is a general opinion that response to periodontal procedures (Preber and Bergström 
1990; Renvert et al. 1998) and the result of periodontal surgery (Boström et al. 1998a) are 
less favourable among smokers. Smoking affects adversely on the long-term prognosis of 
periodontal disease. Smokers are twice as likely to loose teeth compared with non-smokers 
during the maintenance phase (McGuire and Nunn 1996) and up to 90% of refractory 
periodontitis patients are smokers (MacFarlane et al. 1992; Magnusson et al. 1994; 
Magnusson and Walker 1996). 
 
Several studies have demonstrated that the effects of smoking are somewhat reversible, and 
smoking cessation markedly improves the prognosis and outcome of periodontal treatment 
(Grossi et al. 1997; Kaldahl et al. 1996; Scabbia et al. 2001). In comparing former smokers 
with current smokers the prevalence and severity of periodontitis is less (Haber 1994), the 
rate of tooth loss is reduced (Krall et al. 1997) and the progression of bone loss is retarded 
(Bolin et al. 1993) among former smokers. 
 
5.5. COMMONLY USED METHODS FOR DIAGNOSING PERIODONTITIS 
 
5.5.1. Clinical and radiographic diagnosis 
 
Periodontal diseases are quiescent in most cases with minimal clinical signs. Changes are 
often severe before the diagnosis is made. About 8—10% of individuals can develop 
extensive tissue destruction leading to loss of teeth (Papapanou 1999). Clinically, signs of 
inflammation (changed colour and consistency of gingiva, bleeding on probing and 
suppuration) and changes in PD and clinical attachment level (CAL) measured with 
periodontal probe can be observed along with radiological findings. PD and CAL as well as 
radiological findings can tell us about destruction that has already happened. No relevant 
information about the current activity of periodontitis can be achieved with these measures. 
Inflammation is an important finding in periodontal examination. However, other clinical 
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indices except PD fail to predict change in CAL (Adonogianaki et al. 1996). Non-existing 
BOP has been regarded as the golden standard when clinically estimating periodontal health 
status even in deep periodontal pockets. A bleeding site is at 30% risk for loss of attachment 
(Lang et al. 1986), which means that single registration of BOP is of minimal value in 
predicting disease progression (low sensitivity). Lang et al. (1986) regarded the non-existing 
BOP as a good guarantee of non-existing disease (high specificity). Plaque scores are a poor 
predictor of periodontal disease progression (Haffajee et al. 1983; Kaldahl et al. 1990), but 
patients maintaining a good standard of oral hygiene are less in danger of disease recurrence 
or progression even with teeth where the initial prognosis is questionable or hopeless (Chase 
and Low 1993; McGuire 1991). 
 
Deep periodontal pockets are at constant risk of disease progression; depth of gingival 
pockets correlates with future loss of attachment (Claffey and Egelberg 1995; Nieminen 
1997). Individuals with deep periodontal pockets and attachment loss with several bleeding 
sites are at a more severe risk of disease progression than individuals with minimal BOP 
(Claffey et al. 1990). However, there are also reports that the residual probing depth is to a 
lesser extent than BOP a predictor of disease activity (Armitage 1996). 
 
5.5.2. Microbiological diagnosis 
 
Only a few of several hundred recognized species of micro-organisms inhabiting the gingival 
crevice are regarded to play roles in the etiology of periodontal diseases. These few species 
are associated with the initiation and progression of periodontal disease (Socransky and 
Haffajee 1991, 1992). However, the presence of putative periodontopathogens in the gingival 
crevice is not enough to cause periodontal disease: a critical mass of bacteria is needed to 
cause tissue damaging immunomodulatory effects in the susceptible host. 
 
Subgingival plaque can be collected with curettes or by adsorbing subgingival plaque onto 
endodontic paper points for microbiological analysis. With a curette plaque can be collected 
from the entire pocket, while a paper point adsorbs mostly the outer layer of the biofilm 
(Socransky and Haffajee 2002). Each periodontal pocket has a unique microflora, and the 
sample from a few sites only is necessarily not representative of other diseased sites. 
Methods to analyze plaque samples include microscopy, culture techniques, enzymatic 
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assays, immunoassays, nucleic acid probes, and PCR assays. Tests available for the clinician 
can detect only some bacterial and fungal species that have been documented to have an 
etiologic role in periodontal diseases. Microbial culturing on selective or non-selective 
media, though capable of identifying only some bacterial species, has the advantage of 
assessing antibiotic sensitivity. However, low levels of micro-organisms in the sample can 
not be detected. 
 
The sample can be analyzed immediately by microscopy to find out the relative proportions 
of coccal and filamentous-shaped organisms (Offenbacher et al. 1985; Rams 1986). The 
main use of microscopy is to observe the shift in the composition of the flora with 
periodontal therapy but has not been shown to predict the recurrence of the disease 
(Listgarten et al. 1986). 
 
Immunoassays such as immunofluorescense microscopy, enzyme-linked immunosorbent 
assay (ELISA), membrane assays and latex agglutination assays, and nucleic acid probes as 
well as PCR assays have been used for scientific rather than for clinical purposes. These 
methods have higher sensitivity than culture methods but do not permit the evaluation of the 
antibiotic sensitivity of the flora. Some PCR assays can detect virtually all micro-organisms 
in a plaque sample (Zambon and Haraszthy 1995) but micro-organisms which are present in 
plaque in very small quantities may not necessarily contribute to the development and 
progression of periodontal disease. However, findings suggest that neither culture nor 
molecular methods alone can reliably evaluate the oral microbiota and different approaches 
are needed (Tanner and Izard 2005). 
 
Routine testing of periodontopathogens in chronic periodontitis offers limited benefit 
(Jeffcoat et al. 1997). Though bacteria related to periodontal diseases have been studied in 
several investigations, many of these are not valuable if we wish to estimate evidence. A 
systematic review could not find bacterial species or their combinations which could 
differentiate individuals with aggressive periodontitis from those with stable one (Mombelli 
et al. 2002). Moreover, the results of plaque analysis do not give any information regarding 
the risk of disease progression. Microbial diagnosis can be of value, however, in treatment 
planning of periodontitis patients with a poor treatment outcome to meticulous conventional 
mechanical hygiene phase periodontal therapy (SRP), patients suffering from aggressive 
periodontitis or who are medically compromised. 
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5.6. MATRIX METALLOPROTEINASES (MMPs) IN THE PATHOGENESIS OF 
PERIODONTITIS 
 
Human matrix metalloproteinases (MMPs) are a group of at least 23 structurally related but 
genetically distinct endopeptidase enzymes that cleave the internal peptide bonds of proteins 
(Kähäri and Saarialho-Kere 1999). They have the capacity to degrade practically all 
extracellular matrix (ECM) and basement membrane (BM) matrices and components 
(Birkedal-Hansen et al. 1993; Sorsa et al. 2004a) and inactivate and process serpins, growth 
factors, cytokines, cell adhesion molecules, apoptosis factors, and chemokines (Sternlich and 
Werb 2001). In healthy subjects MMPs, along with other extracellular proteinases are 
involved in diverse physiological events such as tissue remodelling, coagulation and 
fibrinolysis, apoptosis, wound repair, bone remodelling, host defence and 
immunomodulatory reactions, regulation of inflammatory responses, reproduction, 
fertilisation, and development. In disease, MMPs are associated with several inflammatory 
conditions involving tissue injury, such as lung, skin and eye diseases as well as diseases of 
skeletal system, and cancer (Owen and Campbell 1999a; Sternlich and Werb 2001; Nyberg et 
al. 2006). MMPs are neutral proteinases and consequently functionally active and 
catalytically competent at physiological pH and temperature (Nyberg et al. 2006). 
 
MMPs are 32—49% homologous at the amino acid level, and most MMPs share a common 
basic five domain prototype structure (Figure 2) (Murphy and Docherty 1992; Nagase et al. 
2005). A typical MMP consists of propeptide of about 80 amino acids, a catalytic 
metalloproteinase domain of about 170 amino acids, a linker peptide which is also called the 
hinge region of variable length, and a hemopexin domain of about 200 amino acids (Nagase 
et al. 2005). MMPs are grouped mainly based on substrate specificity and molecular domain 
structure to 1) interstitial collagenases (MMP-1, -8 and -13), 2) gelatinases (type IV 
collagenases; MMP-2 and -9), 3) stromelysins (MMP-3, -10 and -11), 4) matrilysins (MMP-
7, -26), 5) membrane-type (MT-)MMPs (transmembrane type and GPI-anchored elastase) 
and 6) other MMPs including metalloelastase (macrophage elastase, MMP-12), enamelysin 





Figure 2. Matrix metalloproteinases and their domain structures. Sp, signal peptide; pro, pro-domain; 
cr, proprotein convertase recognition center; cat, catalytic domain; Zn, zinc; FN II, fibronectin type II 
motif; Hpx, hemopexin domain; L, linker; Tm, transmembrane domain; GPI, 
glycosylphosphatidylinositol anchor; Cy, cytoplasmic tail; CysR, cysteine rich domain; Ig, 
immunoglobulin domain. (Modified from Nagase et al. 2005 and Sternlich and Werb 2001.) 
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al. 2005). MMPs are catalytically dependent on intrinsic Zn2+ ions and extrinsic Ca2+ for full 
and optimal activity (Stöcker et al. 1995). 
 
All MMPs are synthesised as inactive proenzymes or zymogens, and their latency is 
maintained by an unpaired cysteine sulfhydryl group near the C-terminal end of the 
propeptide prodomain (Van Wart and Birkedal-Hansen 1990). Thirteen MMPs are secreted 
from the cell as proMMPs and ten MMPs which possess a furin-like proprotein convertase 
recognition center at the end of the propeptide, are likely to be activated intracellularly. 
These latter mentioned MMPs are secreted (MMP-11, -21, -23, -28) or cell surface bound 
(MT-MMPs) as active enzymes (Nagase et al. 2005). Activation is result of at least partial 
removal of the prodomain into a lower molecular weight active form through various 
pathways, such as stepwise or direct extra-cellular activation, activation on the cell surface or 
intracellular activation (Nagase 1997). In vivo MMPs have been suggested to be activated 
alone or in concert with reactive oxygen species and human and bacterial proteinases (Saari 
et al. 1990; Sorsa et al. 1992a, 1997; Moilanen et al. 2003; Nyberg et al. 2006). MMPs have 
somewhat overlapping functions probably as a safeguard against loss of regulatory control, 
which confounds the efforts to understand function of MMPs in vivo (Sternlich and Werb 
2001). 
 
ECM turnover is regulated by a delicate equilibrium between the production, activation, and 
inhibition of proteolytic enzymes. The balance between expression and synthesis of MMPs is 
regulated by their major endogenous inhibitors, tissue inhibitors of matrix metalloproteinases 
(TIMPs) which are synthesised by connective tissue cells and leucocytes and form non-
covalent complexes with MMPs (Murphy et al. 1989). Currently four TIMPs are known with 
different substrate specificities (Brew et al. 2000). TIMP-1 and -2 are soluble inhibitors that 
are present in numerous body fluids (Moses 1997), and TIMP-3 is an insoluble inhibitor 
bound to ECM heparin sulfate proteoglycans and especially expressed in the eye (Langton et 
al. 1998). In addition to TIMPs, MMP activity and activation can be controlled in other ways 
such as proteolytic degradation and inactivation, with chelating agents like EDTA, and by 
non-specific endogenous inhibitor α2-macroglobulin (α2-MG) which is an abundant plasma 
protein and the major inhibitor of MMPs in tissue fluids whereas TIMPs act locally 
(Sternlich and Werb 2001). 
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MMPs influence ECM regulation by altering the composition and structural organization of 
the ECM, thereby altering matrix-derived signals. This proteolytic ECM remodelling results 
in the release of other modular break-down products with biologic activity (Sternlich and 
Werb 2001; Nyberg et al. 2003). Most cells must adhere to natural or provisional matrices to 
survive, thus MMP-mediated disruption of subcellular matrices can induce apoptosis in 
anchorage-dependent cells and plays an important role in normal physiologic cell death 
(Sternlich and Werb 2001). 
 
Gingival tissue extracts, GCF and other samples have shown the type I collagen cleavage 
pattern which is a characteristic of mammalian collagenases [cleaving of native collagen at a 
single locus, resulting in formation of two fragments, (αA) 3/4 and (αB) 1/4 (Mancini et al. 
1999; Uitto et al. 2003; Sorsa et al. 2004a; Safkan-Seppälä et al. 2006)], not of bacterial 
collagenases [attack at multiple sites, producing many short peptide fragments (Sorsa et al. 
1987)]. MMPs are regarded as key mediators in tissue destruction in periodontitis 
(McCulloch 1994a, b; Kinane 2000; Sorsa et al. 2004a, b), and there is evidence that 
irreversible connective-tissue degradation in periodontitis results from an imbalance between 
MMPs and their locally acting tissue inhibitors TIMPs (Ingman et al. 1996; Sorsa et al. 
2004a, b) and collagen degradation of connective tissue and the organic component of bone 
in inflamed periodontal tissues are likely to occur via MMPs (Sodek and Overall 1988; 
Birkedal-Hansen 1993) which eventually act as a cascade (Tervahartiala et al. 2000; Beklen 
et al. 2006). 
 
5.6.1. Role of MMP-8 (collagenase-2) in periodontal connective tissue degradation 
 
Among the MMPs, collagenases (MMP-1, -8 and -13) are the most substrate specific 
regarding their unique capacity to degrade native interstitial collagens. The hemopexin 
domain in their structure is essential for collagenases to cleave the triple helix of collagen 
(Nagase et al. 2005). They can also degrade other matrix macromolecules and inactivate 
serpins as well as modify pro- and anti-inflammatory mediators (Owen and Campbell 1999b; 
Sorsa et al. 2004a; Ala-aho and Kähäri 2005). 
 
MMP-8 (collagenase-2, neutrophil collagenase) is synthesised by differentiating 
granulocytes in the bone marrow and stored in specific granules of circulating neutrophils. 
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However, there are also other cellular sources of MMP-8 such as sulcular epithelial cells, 
gingival and periodontal ligament fibroblasts, monocytes/macrophages, and plasma cells 
(Hanemaaijer et al. 1997; Tervahartiala et al. 2000; Wahlgren et al. 2001; Prikk et al. 2001, 
2002; Sorsa et al. 2004a, b) thus indicating that sulcular epithelial and basal cells can interact 
with the tissue destructive MMP network (Kornman et al. 1997a; Tervahartiala 2003). There 
is also evidence that human cytokine-stimulated synovial and gingival fibroblasts, 
monocyte/macrophages, endothelial cells and joint chondrocytes can express mesenchymal-
type MMP-8 de novo indicating that the regulation of tissue destruction by MMP-8 is more 
complicated than previously known (Weiss 1989; Hanemaaijer et al. 1997; Kiili et al. 2002; 
Sorsa et al. 2004a, b; Cox et al. 2006). 
 
MMP-8 is released from neutrophils in a latent, inactive proform and becomes activated 
during periodontal inflammation by independent and/or combined actions of host-derived 
inflammatory mediators, such as TNFα and IL-1β, and microbial-derived proteases and 
reactive oxygen species (ROS) produced by triggered neutrophils (Weiss 1989; Ryan et al. 
1996; Sorsa et al. 1992a, 2004a). The molecular mass of MMP-8 varies in different 
publications between 50 and 85 kDa, and forms as small as 20 kDa have been reported 
(Seltzer et al. 1981; Hasty et al. 1986; Sorsa et al. 1994) reflecting different degrees of 
MMP-8 glycosylation and/or whether the enzyme is in latent or activated/truncated form. 
Naturally activated MMP-8 obtained from peripheral neutrophils can be detected by 
immunoblotting at 65—70 kDa, and the MMP-8 in GCF migrates primarily as a 60 kDa form 
with smaller amounts of 78 kDa species, corresponding to active and latent forms of the 
enzyme, respectively (Ding et al. 1996, 1997; Romanelli et al. 1999). MMP-8 activity can be 
blocked with TIMP-1 and -2 as well as with tetracyclines (doxycycline), chemically modified 
non-antimicrobial tetracycline-derivatives, bisphosphonates and EDTA (Sorsa et al. 1994; 
Greenwald et al. 1998; Mancini et al. 1999; Teronen et al. 1999; Sorsa and Golub 2005). 
 
The known ECM substrates of MMP-8 are collagens I—III, VII, X, gelatine, proteoglycans, 
bradykinin, angiotensin 1, fibrinogen, substance P, and aggrecan as well as pro- and anti-
inflammatory cytokines/mediators, and MMP-8 can inactivate α2-MG and α1-proteinase 
inhibitor (Owen and Campbell 1999b; Sternlicht and Werb 2001). MMP-8 has been shown to 
play an important role in the periodontal tissue destruction. Especially it is the main 
collagenase in chronic periodontitis (Tervahartiala et al. 2000; Sorsa et al. 2004a, b). MMP-8 
activity is associated also with inflammation related to gingivitis. In gingivitis slightly 
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elevated MMP-8 levels can be detected in GCF but as the latent, inactive proform (Sorsa et 
al. 1988; Lee et al. 1995a). 
 
In chronic periodontitis MMP-8 represents 90—95% of GCF collagenase activity (Lee et al. 
1995a; Ingman et al. 1996; Golub et al. 1997). During the active, progressing phase of 
periodontitis, MMP-8 levels in GCF are significantly elevated, and the MMP-8 will be 
almost completely converted to the active form (McCulloch 1994a, b; Sorsa et al. 1988; Lee 
et al. 1995a; Ingman et al. 1996). Higher levels of collagenase activity have been detected in 
the GCF of patients with progressive loss of periodontal connective tissue attachment 
compared to periodontitis patients whose condition is stable, and gingivitis patients (Lee et 
al. 1995a; Romanelli et al. 1999; Mancini et al. 1999; Pozo et al. 2005). A significant 
decrease in GCF MMP-8 activity following successful periodontal treatment has been shown 
(Lee et al. 1995a; Kiili et al. 2002; Figueredo et al. 2004) and after periodontal treatment 
more collagenase was found to be present in the latent form (Ingman et al. 1993). 
 
Also high levels of active collagenase in salivary and mouthrinse samples seem to reflect the 
periodontal disease status because high levels of collagenase activity have been demonstrated 
both in saliva of patients with untreated chronic periodontitis and localised early-onset or 
aggressive periodontitis (Gangbar et al. 1990; Uitto et al. 1990; Ingman et al. 1993). 
 
MMP-8 is also the major collagenase present in inflamed human gingival tissue (Sorsa et al. 
1988; Ingman et al. 1994a; McCulloch 1994a, b; Kiili et al. 2002). Extracts of periodontitis 
patients’ untreated gingival tissue in contrast to healthy subjects’ gingiva contain 
pathologically elevated levels of MMP-8 in a catalytically active form (Sorsa et al. 1988). 
MMP-8 is also the major MMP present in human mature dental plaque (Sorsa et al. 1995). 
 
Increased MMP-8 levels have been detected also in other inflammatory diseases such as 
rheumatoid arthritis, chronic lung inflammations and eye diseases (Konttinen et al. 1991; 
Prikk et al. 2001, 2002; Holopainen et al. 2003; Määttä et al. 2005, 2006a). Recently MMP-8 
has been shown to exert unexpected anti-inflammatory or protective characteristics in LPS-
induced lung inflammation and allergen-induced granulocytic lung inflammation probably by 
regulating inflammatory cell apoptosis and by processing anti-inflammatory cytokines and 
chemokines (Owen et al. 2004; Sorsa et al. 2004a; Gueders et al. 2005). 
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5.6.2. Other collagenases 
 
Fibroblast-type collagenase MMP-1 (collagenase-1) is transcribed and expressed mainly by 
human fibroblasts but also by keratinocytes, endothelial cells, monocytes/macrophages, 
osteoblasts, chondrocytes as well as malignant tumour cells (Birkedal-Hansen 1993). MMP-1 
is produced as glycosylated proforms of 52 kDa and 57 kDa in size, and as activated species 
the sizes are 42 kDa and 47 kDa, respectively. MMP-1 is also found intracellularly and it 
may act on intracellular proteins (Nagase et al. 2005). MMP-1 is effective in hydrolysing 
type III collagen, but it is less efficient enzyme than MMP-8 in degrading ECM components 
and it is inhibited by TIMP-1. MMP-1 is regarded to be more associated with normal tissue 
remodelling than with tissue degrading processes (Birkedal-Hansen 1993; Ingman et al. 
1994a, Golub et al. 1998). 
 
MMP-1 seems to be associated rather with localised juvenile periodontitis (LJP) than with 
chronic (adult) periodontitis (Suomalainen et al. 1991; Sorsa et al. 1992b). Ingman et al. 
(1996) detected elevated levels of MMP-1 from LJP patients’ GCF compared with adult 
periodontitis (AP) patients’ or healthy controls’ GCF. Low levels of MMP-1 have been found 
to be present in AP GCF (Ingman et al. 1996). This is in concert with the finding reported by 
Haerian et al. (1995) who detected MMP-1 in only 20.8% of all studied periodontitis sites, 
and the levels did not correlate with the periodontal disease status. On the other hand Tüter et 
al. (2002) found elevated levels of MMP-1 in chronic periodontitis patients’ GCF compared 
to periodontally healthy persons, and the levels decreased with hygiene phase periodontal 
treatment. Results from the study made with gingival biopsies from inflamed and healthy 
periodontal tissue also suggested that MMP-1 rather than MMP-8 may play an important role 
in the initiation of collagen degradation in periodontal disease but possibly MMP-8 plays an 
important role in periodontal tissue destruction (Aiba et al. 1996). 
 
Epithelial cells may respond strongly to exogenous factors and produce a variety of bioactive 
molecules such as various cytokines and proteolytic enzymes, like MMP-13 (collagenase-3). 
Expression of MMP-13, first identified in breast carcinomas (Freije et al. 1994), has been 
reported in the pocket epithelium in human periodontitis helping the pocket epithelium to 
invade into periodontal connective tissue (Uitto et al. 1998; Tervahartiala et al. 2000; Kiili et 
al. 2002), and in macrophage-like cells (Kiili et al. 2002) and in fibroblasts. MMP-13 
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degrades type II collagen ten-fold more efficiently than other collagenases (Knäuper et al. 
1996), and it cleaves gelatin efficiently (Lindy et al. 1997). Secreted as 60 kDa glycoprotein, 
it is cleaved to 48 kDa form during proteolytic activation (Moilanen et al. 2003). 
 
Immunoblots for MMP-13 in periodontitis patients’ pre-treatment GCF samples showed 
complex, proenzyme and activated enzyme forms, and following SRP there were significant 
reductions in band absorbance together with clinical parameters (Kiili et al. 2002). This 
finding confirmed results of a study where GCF from periodontitis patients showed active, 
proenzyme and fragmented forms of MMP-13 (Golub et al. 1997; Ilgenli et al. 2006). Ejeil et 
al. (2003) detected decrease in collagen fibres in the presence of MMP-13 with MMPs -2, -9 
and -1 in human gingival explants. They concluded that these metalloproteinases are 
involved in ECM degradation in periodontitis. Cox et al. (2006) showed that gingival 
fibroblasts from chronic adult periodontitis patients cultured in contact with type I collagen 
and stimulated by IL-1β, secreted and activated MMP-13 together with other collagenolytic 
MMPs (MMP-1, -2, -8 and -14). However, Mancini et al. (1999) could not detect MMP-13 in 




Also gelatinases MMP-2 and MMP-9 are suggested to participate in periodontal tissue 
destruction because significantly higher levels of MMP-9 and elevated levels of MMP-2 have 
been found in periodontitis patients’ GCF and the levels decreased with conventional 
periodontal treatment (Mäkelä et al. 1994; Ingman et al. 1996; Westerlund et al. 1996; 
Beklen et al. 2006). Gelatinases further degrade gelatins (collagens that have been denatured 
by interstitial collagenases) as well as collagens IV, V, VII, X and XI, elastin, and BM 
components (Owen and Campbell 1999b; Beklen et al. 2006). Both gelatinases have in their 
structure three repeats of a fibronectin type II motif in the catalytic domain which are 
necessary to effectively cleave type IV collagen, elastin, and gelatins (Nagase et al. 2005). 
 
72 kDa gelatinase A, MMP-2, is produced predominantly by fibroblasts and other connective 
tissue cells. MMP-2 degrades preferentially elastin. Like MMP-1, MMP-2 can act also on 
intracellular proteins (Nagase et al. 2005). MMP-2 has collagenolytic activity, weaker than 
MMP-1 in solution, but it is recruited to the cell surface and is activated by membrane-bound  
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MT-MMPs and may thus express collagenolytic activity near the cell (Nagase et al. 2005). 
Increased levels of MMP-2 have been detected in chronic periodontitis-affected gingival 
tissue localised in close vicinity to the sulcular basement membrane region (Korostoff et al. 
2000; Pirilä et al. 2001). 
 
MMP-9 (gelatinase B) degrades more effectively gelatine as well as collagens types I, II, III, 
V, VI and X, fibronectin, fibrillin, and aggrecan (Konttinen et al. 1998; Kähäri and 
Saarialho-Kere 1999). In periodontitis the major source of MMP-9 is neutrophils and to a 
lesser extent also monocytes/macrophages (Westerlund et al. 1996; Pirilä et al. 2001). MMP-
9 seems to be the major gelatinase in chronic periodontitis gingival tissue, dental plaque, 
saliva and GCF, and the GCF levels are elevated relative to LJP and healthy control GCF 
(Ingman et al. 1994a, b, 1996; Sorsa et al. 1994, 1995; Golub et al. 1995). In GCF collected 
with a mouthrinse method active gelatinase (MMP-9) was detected in the majority of 
periodontitis patients’ samples (97.8%) but in only 11.4% of gingivitis samples (Teng et al. 
1992). The mean gelatinase activity was highest in patients with recurrent loss of attachment 
and/or periodontal abscess formation and during periods of attachment loss, samples from the 
periodontitis group exhibited a two-fold increase of mean gelatinase activity. Seguier et al. 
(2001) suggested that MMP-9 could be a marker for the clinical severity of periodontal 
disease based on their cross-sectional study. 
 
5.6.4. Other MMPs with a role in periodontitis 
 
The stromelysin sub-family members MMP-3 (stromelysin-1), MMP- 10 (strolemysin-2), 
MMP-11 (stromelysin-3) and macrophage metalloelastase (MMP-12) do not cleave collagen 
themselves but they act synergistically with collagenases and gelatinases, and they also 
degrade proteoglycans and BM components. Stromelysins can activate other proMMPs 
including MMP-1, -8, -9, and -13 (Kähäri and Saarialho-Kere 1999; Moilanen et al. 2003; 
Beklen et al. 2006). They are expressed by various cell types as fibroblasts, endothelial cells, 
keratinocytes, and chondrocytes. MMP-11 can be activated intracellularly like MMP-1 and -
2 (Nagase et al. 2005). GCF stromelysin in cascade together with MMP-8 and -9 levels 
differentiate periodontitis sites from healthy sites and have been found to correlate 
moderately with clinical indices (Haerian et al. 1995; Beklen et al. 2006). 
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MMP-3 (stromelysin-1) is produced by gingival connective tissue cells and it plays a 
significant role in the activation cascade of latent proMMPs -1, -8, -9, and -13 (Kähäri and 
Saarialho-Kere 1999; Moilanen et al. 2003). MMP-3 can degrade a wide range of 
extracellular matrix components including fibronectin, laminin, elastin and gelatin. In a 
longitudinal study Alpagot et al. (2001) detected significantly higher levels of MMP-3 and its 
endogenous inhibitor TIMP-1 in periodontitis sites than in GCF from healthy sites, and the 
levels were higher in progressing than in non-progressing sites. Thus MMP-3 was found to 
correlate with clinical findings, and it was concluded that sites with high levels of MMP-3 
and TIMP-1 together with MMP-8 and -9 are at risk of progression of periodontitis (Beklen 
et al. 2006). This is in accordance with the finding by Haerian et al. (1995) who found that 
the mean amounts of stromelysins and TIMP-1 in diseased sites (gingivitis and periodontitis) 
were significantly higher than the mean amount of these GCF components in healthy sites, 
and GCF stromelysins and TIMP-1 differentiated healthy from diseased sites both correlating 
moderately with clinical indices. However, Ingman et al. (1996) found only relatively low 
levels of MMP-3 in AP as well as in LJP GCF and low levels of TIMP-1 in AP GCF. 
 
The matrilysin subgroup member MMP-7 (matrilysin-1) is synthesised by epithelial cells 
and it can degrade several ECM and BM components (for example collagens type IV and IX, 
laminins and fibronectin) as well as activate TNF-α, and several proMMPs including 
proMMP-8 (Balbin et al. 1998). It may be related to epithelial migration (Dunsmore et al. 
1998) and in the normal physiology and antibacterial defence of junctional epithelium (Uitto 
et al. 2003). Matrilysin is expressed in the suprabasal cells of the normal human junctional 
epithelium facing the teeth and in epithelial cell rests of Malassez (Uitto et al. 2002). MMP-7 
has been detected in periodontitis-affected GCF and peri-implant sulcus fluid (PISF) 
correlating with MMP-8 reflecting especially the severity of peri-implantitis (Tervahartiala et 
al. 2000; Kivelä-Rajamäki et al. 2003a; Sorsa et al. 2004a, b). 
 
Membrane type matrix metalloproteinases (MT-MMPs) are not, like other MMPs, 
usually secreted as soluble proforms, but instead they mainly exert their activity on the cell 
surface. However, cultured gingival fibroblasts from periodontitis patients can express and 
release a soluble form of MMP-14 (Cox et al. 2006), which can be detected in periodontitis 
affected GCF (Tervahartiala et al. 2000) and inflammatory tear fluid and bronchoalveolar 
lavage fluid (Maisi et al. 2002; Holopainen et al. 2003). MMP-14 can activate other MMPs 
among them proMMP-8 and -13, and it has been detected in fibroblasts from inflamed 
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human gingival specimens (Dahan et al. 2001; Holopainen et al. 2003; Cox et al. 2006). 
MMP-14 can degrade, among other substrates, collagens I—III and thus activate proMMP-2, 
-13, and -8 (Sternlich and Werb 2001). Also enhanced levels of leukolysin (MT2-MMP or 
MMP-25) together with matrilysin-2 (MMP-26) have been detected in periodontitis-affected 
GCF (Emingil et al. 2006a). 
 
5.7. GINGIVAL CREVICULAR FLUID (GCF) 
 
GCF is an important local defence mechanism of the periodontal pocket. Production of GCF 
is directly related to the dilatation and increased permeability of blood vessels in the gingival 
connective tissue. In the healthy periodontal sulcus GCF is an exudate of serum origin and 
excreted in small amounts. With an increase of the severity of periodontal inflammation the 
amount of GCF excretion increases significantly (Armitage 1995). Because most clinical 
periodontal indices are somewhat subjective in nature, quantification of GCF volume has 
been used as an objective measurement of periodontal tissue inflammation in scientific 
research and to evaluate the inflammatory status of periodontal tissues (Brill 1960). 
 
In inflamed gingiva GCF is an inflammatory exudate derived from a number of sources, 
including serum, the connective tissue and epithelium through which GCF passes on its way 
to the gingival crevice. As fluid traverses the inflamed tissue, enzymes and other molecules 
as well as products of cell and tissue remodelling and degradation of host and bacterial origin 
are collected. The cellular components of GCF are 70—80% neutrophils, 10—20% 
monocytes/macrophages, 5% mast cells and 5% T-lymphocytes. 
 
The rich array of cellular and biochemical mediators in GCF reflect the metabolic status of 
periodontal tissues. GCF has the benefit of being closely approximated to the specific site of 
periodontium thus providing more information about periodontal status than markers for 
example in serum or urine. Though the risk for periodontal disease is patient based, the 
progression of periodontitis takes place on a tooth site level (Champagne et al. 2003). Thus 
GCF offers the possibility to monitor the pathologic processes of destructive periodontitis 
lesions site specifically and provides diagnostic information beyond that provided by the 
traditional clinical examination (Lamster et al. 1985). 
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Decreased GCF flow in smokers has been reported (Hedin et al. 1981; Persson et al. 1999). 
However, McLaughlin et al. (1993) found that following smoking there was more than a 
two-fold increase in GCF output compared to sham smoking (smoking movements with an 
unlit cigarette), and the heaviest smokers produced highest GCF volumes. In periodontally 
healthy subjects after smoking cessation GCF flow increased to comparable levels with non-
smokers suggesting that the gingival microcirculation recovers in a few days after smoking 
cessation in periodontal health (Morozumi et al. 2004). 
 
5.7.1. Potential disease markers in GCF 
 
Great interest has focused on gingival crevicular fluid in the determination of current 
periodontal status and as a possible predictor of periodontal disease progression. GCF has 
been analysed since the 1930’s to identify biomarkers of periodontal disease activity. Studies 
have shown that there is a generalised increase in GCF protein content at sites of active 
infection as well as an increase in GCF production. Over 65 components have been 
preliminary examined with the purpose to find a possible marker or markers which could 
identify the sites that are in the risk of periodontal disease progression, i.e. additional loss of 
attachment (Armitage 2004). 
 
One problem to be solved when biomarkers in GCF are used for diagnostic purposes is the 
diagnostic potential of the biomarker measured as a concentration in GCF or as total amount 
in the sample (see also Tables 1 and 4). GCF volume increases in order of healthy, gingivitis, 
and periodontitis (Nakamura et al. 2000) and the volume of GCF recovered with paper filter 
strips is directly related to the periodontal pocket probing depth (Gamonal et al. 2000a). 
However, increased GCF flow does not necessarily reflect the periodontal disease activity. 
The concentration of biomarkers in GCF can be affected by the volume. Excess GCF flow, 
especially in an inactive site may dilute the concentration of the biomarker (Gamonal et al. 
2000a). Though significantly higher GCF volumes and amounts of total proteins in GCF 
samples are obtained from periodontitis patients compared with control subjects (Vernal et 
al. 2005) neither total amount nor concentration of individual biomarker in GCF necessarily 
correlates with periodontal parameters (Gamonal et al. 2000a). In the case of some 
biomarkers a correlation may be found for either detection method (Nakamura et al. 2000; 
Vernal et al. 2005). 
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GCF can be harvested from the gingival pocket with paper filter strips or micropipette tubes 
using an intracrevicular washing method. The intracrevicular washing method for collection 
of gingival crevicular components (cells and chemical components) was introduced by 
Salonen and Paunio (1991), and the method has further been modified by Figueredo and 
Gustafsson (1998). In the method a small amount of washing solution is manually ejected 
through a tiny needle into the bottom of the gingival crevice, and the solution is immediately 
collected with continuous aspiration at the gingival margin with a collecting needle into a 
sample tube. 
 
The collection time influences the composition of the collected GCF and a long sampling 
time especially with micropipettes, may irritate the tissue and enhance the vascular 
permeability and change the composition of GCF. Sampling time of 30 s or less is 
recommended (Eley and Cox 1998a) but variable sampling times from 5 s (Talonpoika and 
Hämäläinen 1994) to 3 min (McLaughlin et al. 1993) can be found from literature reviewed 
in this thesis. With paper filter strips, most of the enzymatic activity of GCF is depleted 
during the first few seconds of sampling, and more than 10 min is required before 
equilibrium is regained (Persson and Page 1990). 
 




Most of the potential periodontal disease markers in GCF originate from neutrophils, 
monocytes/macrophages, mast cells and T lymphocytes; the first two mentioned being the 
most essential part of the host’s inflammatory response in GCF. Proteinase enzymes are 
endopeptidases which are resident in inflammatory cells but also in tissue cells. All of them 
can degrade ECM and BM proteins in vivo. They are grouped into four groups based on the 
biochemical nature of the active site: 1) serine proteinases, 2) matrix metalloproteinases 
(already discussed in the previous section), 3) cysteine proteinases, and 4) aspartate 
proteinases. The first two mentioned groups are most active at neutral pH (neutral 
proteinases) and they mediate most extracellular in vivo proteolytic events. Cysteine 
proteinases and aspartate proteinases are optimally active at acidic pH in phagolysosomes 
(intracellular proteolysis), but these acidic proteinases can take part in extracellular 
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proteolysis if they are released at sufficiently high concentration into an acidic environment 
(Owen and Campbell 1999a). 
 
Neutrophils form the first line of defence against a bacterial challenge in the periodontal 
pocket, and they have a highly protective role in inflammatory reactions. Over 90% of 
leukocytes in GCF are neutrophils (Uitto et al. 2003; Sorsa et al. 2004a, b). Leukocyte 
derived proteinases have the capacity to degrade almost all components and matrices of the 
ECM and basement membranes as well as extracellular proteins like complement 
components, clotting factors, immunoglobulins, and pro- and anti-inflammatory mediators 
(Owen and Campbell 1999a, b; Gueders et al. 2005). If the control of the activity of these 
enzymes is disturbed, they contribute to tissue injury in several organs as well as in the 
periodontium. Neutral proteinases from neutrophils also facilitate neutrophil migration and 
help to create an environment for effective defence against microbes (Uitto et al. 2003). 
Thus, neutrophil proteinases (MMP-8 and -9) can exert anti-inflammatory protective 
characteristics (Owen et al. 2004; Sorsa et al. 2004a; Gueders et al. 2005). 
 
The proteinase enzymes found in the GCF which are associated with the pathogenesis of 
periodontitis and which may be of possible diagnostic value are shown in Table 1: 
 
 Neutrophil elastase, a serine proteinase that is released from neutrophil azurophilic 
granules during phagocytosis stimulation and cell lysis. Elastase, like other serine 
proteinases, has broad substrate specificity, and it is capable of degrading a variety of 
human tissue molecules such as collagens, laminins, fibronectin, proteoglycan and 
elastin, and it may have some direct anti-microbial effects. The superior correlation of 
total elastase activity compared to concentration, with clinical parameters of 
periodontal disease has been shown in several studies. 
 Human serine proteinase cathepsin G may contribute to periodontal tissue 
destruction directly or via proteolytic activation of latent neutrophil procollagenase, 
and it may regulate vascular permeability and monocyte chemotaxis (Owen and 
Campbell 1999b). Cathepsin G can activate proMMP-8 and -9 (Kähäri and Saarialho-
Kere 1999). Thus part of the cathepsin G can exist as an uncomplexed, free and 
functionally active form and thus reflect the disease process of gingiva (Tervahartiala 
et al. 1996). 
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 Plasminogen activators are two types of serine proteinases, the tissue/blood vessel 
type (t-PA) and the urokinase type (u-PA). Both of these are expressed in fibroblasts 
(Dano et al. 1985; Saksela 1985) and u-PA in gelatinase (tertiary) granules and 
primary granules in neutrophils (Borregaard et al. 1995). This system acts in both 
physiological (cell migration, wound healing, tissue remodelling, fibrinolysis, and 
inflammation) and pathological (malignant cell invasion) processes and is important 
in extracellular proteolysis by converting the proenzyme plasminogen into the broad-
spectrum serine proteinase plasmin which in turn can activate certain latent proMMPs 
(Kruithof 1988). 
 Lysosomal cysteine proteinases cathepsin B, H and L which have been localised to 
fibroblasts, monocytes, macrophages, and neutrophils. 
 Aspartate proteinase cathepsin D which is released at the endpoint of inflammation. 
 Myeloperoxidase (MPO). The myeloperoxidase-hydrogen peroxidase-chloride 
system with antimicrobial activity from neutrophil primary granules has been 
implicated as part of innate host defence. 
 Beta-N-acetyl-hexosaminidase (ß-NAH), a lysosomal acid hydrolase released into 
GCF subsequent to phagocytosis by the neutrophil. 
 Neutrophil primary granule acid glycohydrolase enzyme ß-glucuronidase (ß-G) 
which is involved in the destruction of non-collagenous component of extracellular 
matrix  
 Lactoferrin that is released from neutrophil secondary granules and acts directly on 
the bacteria to prevent their growth. 
 Alkaline phosphatase (ALP) secreted by neutrophils and other inflammatory cells 
has a role in areas of high bone turnover. 
 
Monitoring the combination of several biochemical parameters might provide more 
information in order to predict future periodontal disease progression compared to 
measurement of a single biomarker. However, in a longitudinal study of chronic periodontitis 
patients in maintenance care unspecified neutral protease activity detected in GCF appeared 
to differentiate bleeding sites exhibiting only chronic inflammation but not the attachment 
loss (Bader and Boyd 1999). Nakashima et al. (1996) monitored adult periodontitis patients 
for one year and measured a combination of protease enzymes (ALP, collagenase and β-G). 
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Table 1. Proteinase enzymes in GCF. For each study the main findings are indicated in the table. 



























































Elastase       
Eley and Cox 1992a    ▲   
Armitage et al. 1994* ▲      
Ingman et al. 1994b    ▲   
Murray et al. 1995   ■●    
Eley and Cox 1996a ▲■      
Meyer et al. 1997    ▲   
Jin et al. 1999      ▲ 
Yamalik et al. 2000   ▲     
Herrmann et al. 2001     ▲  
Jin et al. 2002    ▲  ▲ 
Cathepsin G       
Suomalainen 1992    ▲   
Kunimatsu et al. 1995   ▲ ■   
Plasminogen activators       
Yin et al. 2000    ■   
Cathepsin B, H and L       
Kunimatsu et al. 1990 (B, H, L)   ▲ ▲   
Eley and Cox 1992a, b, c (B)  ▲     
Eley and Cox 1992a (B, L)  ■▲     
Eley and Cox 1996b* (B) ■▲      
Chen et al. 1998 (B)  ▲     
Cathepsin D       
Buchmann et al. 2002a*, b*    ▲   
MPO       
Buchmann et al. 2002a*, b*    ▲   
ß-NAH       
Buchmann et al. 2002a*, b*    ▲   
ß-G       
Lamster et al. 1988  ▲     
Grbic et al. 1995   ▲    
Lamster et al.1994a   ▲     
Lamster et al 1995* ?▲      
Grbic et al. 1999*     ■  
Buchmann et al. 2002a*    ▲   
Layik et al. 2000   ▲ ▲   
Lactoferrin       
Adonogianaki et al. 1993  (■)   ■  
Gustafsson et al. 1994   ■    
Murray et al. 1995  ● ■    
Figueredo and Gustafsson 2000   ■●    
ALP       
Chapple et al. 1994     ■  
Nakashima et al. 1994    ■●   
Chapple et al. 1999 * ●           
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They found significantly elevated levels of studied proteases from active relative to inactive 
sites prior to attachment loss without any significant differences in GCF volume and clinical 
indices. When Hanioka et al. (2005) studied 12 potential biomarker substances in GCF by 
regression analysis to find a combination which identifies sites with periodontal destruction, 
the combination of IgA and neutrophil elastase provided the most satisfactory predictive 
model for diagnosing the periodontal disease status. 
 
5.7.1.1.2. Proteinase inhibitors 
 
Proteinase levels in gingival tissue are determined partly by the balance between the enzyme 
and its natural inhibitors. The level of enzyme in the tissue and in GCF depends therefore to 
some extent upon the enzyme-inhibitor balance. 
 
A number of proteinase inhibitors as possible markers of periodontitis have been studied 
(Table 2): 
 
 α1-proteinase inhibitor, most abundant of specific inhibitors, serpins that regulate 
the serine proteinase activity in tissues. It is produced mainly by hepatocytes but also 
by activated neutrophils. 
 α2-MG 
 α1-antitrypsin (α1-AT) 
 Tissue inhibitors of metalloproteinases (TIMPs) which perform the extracellular 
control of interstitial collagenases and other MMPs. TIMP-1 especially is expressed 
by many cell types including host fibroblasts, keratinocytes, monocytes/macrophages, 




Table 2. Proteinase inhibitors in GCF. For each study the main findings are indicated in the table. 





























α1-proteinase inhibitor      
Ingman et al. 1994b    ■  
Meyer et al. 1997   ■   
Buchmann et al. 2002b  ■    
α2-MG      
Adonogianaki et al. 1996   ■  ■ 
Chen et al. 1998  ■    
α1-AT      
Adonogianaki et al. 1996   ■  ■ 
TIMPs      
Haerian et al. 1995  (■)    
Ingman et al. 1996  ■    
Alpagot et al. 2001* ■   ■  
Tüter et al. 2002    ■ (r)  
Pozo et al. 2005  ■ (r)    
 
 
5.7.1.1.3. Other enzymes originating from host cells 
 
 The levels of aspartate aminotransferase (AST), cytoplasmic enzyme released from 
damaged or necrotic cells during inflammation, have been used by measuring it in 
serum as an indicator of cell death that occurs in a variety of systemic disorders such 
as those following myocardial infarction. It could also provide evidence of cell death 
within the periodontal tissues and of possible disease activity. 
 Calprotectin is a cytosol protein expressed by neutrophils, monocytes, activated 
macrophages and squamous mucosal epithelia. It is known to have a broad spectrum 
of in vitro antimicrobial effects (Nisapakultorn et al. 2001a) and its expression 
inhibits bacterial binding to mucosal epithelial cells (Nisapakultorn et al. 2001b). 
 Creatine kinase and lactate dehydrogenase 
 Glycosidase 
 Dipeptidyl peptidase II- and IV -like activity. (Table 3) 
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Table 3. Other enzymes in GCF originating from host cells. For each study the main findings are 






































AST      
Persson et al. 1990* ▲     
Chambers et al. 1991* ■     
Atici et al. 1998   ▲   
Smith et al. 1998   ▲   
Kuru et al. 1999     ▲ 
Wong et al. 1999     ▲ 
Shimada et al. 2000  ▲    
Kamma et al. 2001     ▲ 
Creatine kinase and lactate 
dehydrogenase 
     
Atici et al. 1998   ▲   
Glycosidase      
Beighton et al. 1992  ▲    
Dipeptidyl peptidase II- and 
IV -like activity 
     
Cox et al. 1992   ▲   
Eley and Cox 1992a   ▲   
Eley and Cox 1995* ▲■     
Calprotectin      
Kido et al. 1999  ■    
Lundy et al. 2000   ■   
Nakamura et al. 2000    ■  
 
 
5.7.1.2. Inflammatory and immune markers in GCF 
 
Cytokines 
Cytokines, described as local hormones or cell to cell messengers, are small soluble proteins 
or peptides. More than 100 cytokines are known, among them chemotactic cytokines 
(chemokines), interleukins, interferons, and tumour necrosis factors. Cytokines control cell 
growth and differentiation, stimulate (chemokines and pro-inflammatory cytokines) or 
subdue (anti-inflammatory cytokines, interferons) the inflammation and regulate the 
development of the antimicrobial immunity in cooperation with antigen presenting cells 
(Julkunen et al. 2003). 
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A summary of the following cytokines with a specific role in periodontitis is presented in 
Table 4: 
 
 IL-1, a cytokine with pro-inflammatory effects and a potent stimulator of bone 
resorption is produced by activated macrophages, monocytes, B cells, neutrophils, 
fibroblasts, and epithelial cells. It is involved in pro-inflammatory process, matrix 
degradation, and wound healing (McCauley and Nohutcu 2002).  
 IL-8 is a potent chemotactic and activating factor for neutrophils, and it is thought to 
provide protection against periodontal infections by enhancing host defence 
mechanisms. 
 IL-6 is a macrophage and T-cell originating cytokine. Healing of periodontal pockets 
may be affected by an accumulation of IL-6 in the adjacent connective tissue as a 
result of increased synthesis or reduced release into the GCF (Guillot et al. 1995). 
 TNF-α is a monocyte/macrophage-derived pro-inflammatory cytokine which can 
stimulate proteolytic enzyme synthesis and osteoclast activity. 
 The chemokine RANTES, a chemoattractant cytokine of T-cell origin is a potent 
chemoattractant for inflammatory cells and may play a role in host response in active 
inflammation. 
 Receptor antagonist of IL-1 (IL-1ra) 
 
Immunoglobulins 
Potential immune mediators relevant to periodontal pathology are immunoglobulins. 
Antigens from periodontopathogenic bacteria induce antibody production, and both serum 
and locally produced antibodies can be detected in GCF. However, with the current 
knowledge neither specific antibody nor total GCF-Ig seems to be valuable in distinguishing 
between stable and progressing sites or patients at risk (Table 5). The role of IgA in GCF 
may be protective (Lamster et al. 1994b), and maintenance of high levels of IgA in GCF may 
protect from progression of periodontal tissue destruction (Grbic et al. 1999). 
 
Ebersole and Cappelli (1994) identified antibody isotypes and subclass proportions of IgG in 
GCF in periodontitis patients with A. actinomycetemcomitans cultivated from subgingival 
plaque. They found that over 95% of sites with elevated IgG4 were colonized with A. 
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actinomycetemcomitans, and less than 50% of sites with elevated IgG2 were positive for A. 
actinomycetemcomitans. Sites infected with P. gingivalis in patients diagnosed to suffer of  
 
Table 4. Cytokines in GCF. For each study the main findings are indicated in the table. 





























IL-1 (α, β)     
Masada et al. 1990    ■ 
Reinhardt et al. 1993   ■  
Holmlund et al. 2004    ■ 
IL-1α   
 
  
Mathur et al. 1996    ■● 
IL-1β     
Wilton et al. 1993    ■  
Hou et al. 1995  ● ■  
Lee et al. 1995b* ■    
Tsai et al. 1995  ●   
Salvi et al. 1997  ■   
Figueredo et al. 1999   ■ ■ 
Gamonal et al. 2000b* ■ ●   
Rawlinson et al. 2000  ■   
Engebretson et al. 2002*  ■  ■ 
Rawlinson et al. 2003    ■ (r)   
Goutoudi et al. 2004*  ●   
IL-1ra      
Rawlinson et al. 2000, 2003  ■ (r)   
Holmlund et al. 2004    ■ 
IL-8     
Tsai et al. 1995  ●   
Mathur et al. 1996    ● ■(r) 
Ozmeric et al. 1998 (LJP)   ■●  
Gamonal et al. 2000b*  (●)  ■ 
Gamonal et al. 2001    ■ 
Jin et al. 2002     ■ 
IL-6     
Reinhardt et al. 1993 (refr.)  ●   
Lee et al. 1995b* (refr.) ■    
Guillot et al. 1995  ■ (r)   
TNF-α      
Rossomando et al. 1990   ■ ■ 
Lee et al. 1995b*   ■  
Tervahartiala et al. 2001 (tissue 
specimens) 
   ■ 
RANTES     
Gamonal et al. 2000a  ■● ■  ● 
Gamonal et al. 2000b*  (●)  ■ 
Gamonal et al. 2001    ■ 
Emingil et al. 2004a  ■   
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rapidly progressing periodontitis manifested high levels of specific antibody, levels 
correlated with clinical status and antibody levels decreased significantly after successful 
SRP with reduction of PD and resolving of inflammation (Johnson et al. 1993). 
 
Other inflammatory media ors t
Monocytic inflammatory mediator prostaglandin E2 (PGE2) is a metabolite of arachidonic 
acid and a potent biochemical mediator of inflammation with many proinflammatory effects. 
It can induce indirectly the destruction of ECM components of connective tissue by initiating 
vasodilatation, increasing capillary permeability and enhancing inflammatory cell infiltration. 
(Table 5) 
 
Table 5. Immunoglobulins and other inflammatory mediators in GCF. For each study the main 




































Total Ig       
Lamster 1992   ■   
Page 1992   ■   
IgA      
Grbic et al. 1995   ■ (r)   
IgG subclasses (IgG1, IgG2, 
IgG3, IgG4) 
     
Sengupta et al. 1990   ■ ■  
Johnson et al. 1993  ■  ■  
Wilton et al. 1993    ■   
Ebersole and Cappelli 1994    ■  
Other inflammatory mediators 
PgE2      
Offenbacher et al. 1984* ■     
Offenbacher et al. 1986* ■     
Heasman et al. 1993     ■ 
Nakashima et al. 1994  ■  ■  
Salvi et al. 1997  ■    
Jin et al. 1999   ■   
Leibur et al. 1999    ■  
Preshaw and Heasman 2002   ■ ■  
C-reactive protein (CRP)       
Sibraa et al. 1991   ■   
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5.7.1.3. Tissue-breakdown products in GCF 
 
Components of collagen breakdown products and other gingival connective tissue structures 
in GCF may serve as measures of periodontal connective tissue and basement membrane 
catabolism and have been considered as possible markers of bone resorption and periodontal 
disease activity. 
 
Bone resorption markers 
 Osteonectin (also known SPARC), a non-collagenous calcium-binding protein in the 
extracellular matrix in many tissues, is liberated from many different cell types as a 
heat shock protein, but may be related to inflammation in general (McCauley and 
Nohutchu 2002). 
 Osteocalcin (OC) is a non-collagenous protein, which is a major component of bone 
extracellular matrix and mainly produced by osteoblasts. It can also be considered as 
a marker of bone turnover. Some of this protein is derived from circulation but 
osteocalcin may be produced also locally and released into GCF by osteoblast 
activity. 
 The pyridinoline cross-linked carboxyterminal telopeptide of type I collagen 
(ICTP) is a sensitive marker of bone resorption in osteolytic disease such as 
osteoporosis and osteoarthritis and a sensitive indicator of periodontal tissue 
destruction (Giannobile 1999). 
 Osteopontin (OPN) is a glycosylated phosphoprotein in the bone matrix produced by 
several cell types including osteoblasts, osteoclasts and macrophages in sites of active 
bone metabolism. (Table 6) 
 
Connective tissue and basement membrane degradation markers 
The detection of components of degraded connective tissue or sulcular basement membrane 
which have passed to GCF could be indicative of tissue breakdown or active pocket 
formation associated with periodontal disease progression. 
 
 Laminin is a glycoprotein found in all basement membranes. Emingil et al. (2004b, 
c; 2006b) showed that an adjunctive host response modulating low-dose doxycycline 
(LDD) therapy in combination with SRP therapy reduced GCF laminin-5 gamma2-
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chain fragment levels together with MMP-8 levels and improved clinical periodontal 
parameters in patients with chronic periodontitis. Also in PISF laminin-5 gamma2-
chain fragments have been found to correlate with clinical markers of peri-implantitis 
severity and PISF MMP-8 and -7 (Kivelä-Rajamäki et al. 2003a, b). The proteolytic 
processing of laminin-5 gamma2 chain in human inflamed periodontium is eventually 
conducted by human MMPs (Pirilä et al. 2001, 2003) since the fragmentation of 
laminin-5 gamma2 chain in periodontitis affected GCF (Emingil et al. 2004b, c, 
2006b) resembles that done by human MMPs (Pirilä et al. 2003) and not that done by 
P. gingivalis trypsin-like protease (Emingil et al. 2006b). 
 Fibronectin is concerned with the cell adhesion of connective tissue and can be 
found also in GCF. 
 Hydroxyproline-containing peptides are released during fibrillar collagen 
degradation. 
 The extracellular ground substance of connective tissue is comprised of high 
molecular weight aggregates, proteoglycans, constituted of glycosaminoglycans 
(GAGs). Connective tissue breakdown in periodontitis includes proteoglycan 
degradation with release of GAGs which pass into GCF. A rather large sample of 
GCF is needed (15 min sampling with micropipettes) to detect GAGs which reduces 
the value in chair-side diagnostics (Eley and Cox 1998b). Chondroitin-4-sulphate can 
also be detected from GCF of teeth undergoing orthodontic movement, showing 
evidence of trauma from occlusion, and from healing tooth-extraction wounds thus 
correlating with clinical conditions where degradative changes are occurring in 
deeper parts of periodontal tissues (Last et al. 1985). 
 Decorin and biglycan, small proteoglycan metabolites. (Table 6) 
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Table 6. Tissue break-down products in GCF. For each study the main findings are indicated in the 
















No correlation with 
clinical parameters 
or disease severity 
Elevated levels in 
periodontitis 
Bone resorption markers 
Osteonectin (SPARC)    
Bowers et al. 1989 ■   
OC    
Kunimatsu et al. 1993 ■   
Nakashima et al. 1994 ■   
Lee et al. 1999  ■  
ICTP    
Talonpoika and Hämäläinen 1994 ■   
Oringer et al. 1998 (peri-implantitis) ■   
Palys et al. 1998 (■)  ■ 
Al-Shammari et al. 2001* ■   
OPN    
Kido et al. 2001 ■   
Connective tissue and basement membrane degradation markers 
Laminin    
Figueredo and Gustafsson 2000   ■ 
Emingil et al. 2004b, 2006b   ■ 
Kivelä-Rajamäki et al. 2003a, b (peri-
implantitis) 
■   
Fibronectin    
Lopatin et al. 1989   ■ (r) 
Talonpoika et al. 1993 ■   
Huynh et al. 2002   ■ 
Hydroxyproline    
Akalin et al. 1993  ■  
GAGs    
chondroitin-sulphate    
Okazaki et al. 1995   ■ 
Smith et al. 1995 ■  ■ 
hyaluronic acid     
Last et al. 1985  ■  
Decorin and biglycan    
Waddington et al. 1998   ■ 
 
5.7.1.4. Enzymes of bacterial origin in GCF 
 
The ability of bacteria to directly damage periodontal tissues is limited though a number of 
periodontopathogenic bacteria produce several proteolytic enzymes that are important 
virulence factors for these microbial species. Thus part of the proteolytic activity in GCF can 
be ascribed to bacterial proteases while neutrophils, present in large numbers at inflamed 
sites, are mainly responsible for the proteolytic activity (Sorsa et al. 2004a, b). Enzymes from  
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P. gingivalis and A. actinomycetemcomitans can participate in periodontal disease 
progression by producing immunoglobulin degrading enzymes in LJP detectable in GCF 
(Gregory et al. 1992). Measurement of these enzymes in GCF is complicated because of their 
very broad substrate specificity, their rather uncharacterised protein structures, a lack of 
specific enzymatic assays for their measurements, and their tight association with bacterial 
cell membranes (Uitto et al. 2003). 
 
Trypsin- and tryptase-like activity of can be detected in higher levels from chronic 
periodontitis GCF compared to healthy subjects (Eley and Cox 1992a). In addition, the 
presence of bacterial dipeptidyl peptidase originating from P. gingivalis has been detected 
in GCF (Gazi et al. 1995). A 2-year longitudinal study indicated that both bacterial 
gingivain/gingipain and dipeptidyl peptidase may be predictors of periodontal attachment 
loss with higher positive predictive values for gingivain/gingipain (Eley and Cox 1996c). 
 
5.7.2. Effect of smoking in GCF biomarkers 
 
Smoking appears to affect the normal balance of several cytokines as well as of other GCF 
biomarkers (Table 7). Smoking decreases mean GCF IL-1α concentrations significantly but 
does not affect mean total protein concentration of samples. Neutrophil numbers are not 
significantly different between S and NS suggesting that the reduced IL-1α concentration in 
S is independent of any effect of smoking on neutrophil chemotaxis, and smoking may 
directly inhibit IL-1α production (Petropoulos et al. 2004). Thus GCF IL-1α may be derived 
from the inflamed tissues rather than being locally produced by neutrophils in the gingival 
pocket. 
 
The influence of smoking on neutrophil elastase activity under healthy or slightly inflamed 
conditions is limited (Persson et al. 1999). Contradictory findings concerning elastase in 
GCF of smoking subjects  with periodontal disease have been reported. Lower concentrations 
of functional elastase in S than NS GCF led to the hypothesis that smokers’ PMNs may 
release elastase prior to reaching the periodontal tissues, for example during passing through 
the lungs, or possibly a greater proportion of the elastase is bound to its substrate and remains 
undetected thereby complicating the diagnostic value of GCF elastase in smokers (Alavi et 
al. 1995). 
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It has also been concluded that decreased local levels of enzyme inhibitors may result in 
increased tissue damage due to an increased activity of elastase and collagenase (Persson et 
al. 2001). Following surgical treatment, in the S group the levels of GCF α1-AT, α2-MG and 
MMP-8 remained unaltered, and in the NS group the levels decreased indicating a more 
favourable treatment outcome, and elastase remained unaltered in both groups (Persson et al. 
2003). Söder (1999) showed that smokers’ periodontal sites with high levels of MMP-8 were 
significantly deeper compared with sites with low levels. Moreover, a positive correlation 
between PD and levels of MMP-8 both in S and NS patients with refractory periodontal 
disease existed. Also, significantly higher PGE2 levels were detected in sites with high levels 
of MMP-8 than in those with low levels (Söder 1999). In a regularly maintained periodontitis 
population, levels of PGE2 in S than NS GCF were significantly lower (Söder et al. 2002). 
On a population basis smoking as a risk of periodontal disease does not appear to correlate 
with an elevation of GCF-PGE2 (Heasman et al. 1998). 
 
A soluble form of intercellular molecule-1 (sICAM-1) is known to be elevated in the 
circulation of S compared to NS subjects (Koundouros et al. 1996). Conversely, in the GCF 
of subjects with periodontitis sICAM-1 was significantly lower in S compared with NS 
(Fraser et al. 2001). The difference in GCF concentrations of sICAM-1 compared with serum 
(4-fold in serum) was significant in S but not in NS subjects. sICAM-1 molecules may 
possibly bind to sequestrated neutrophils in periodontal microvasculature and provoke the 
release of neutrophil elastase. This results in inappropriate endogenous protease release, 
contributing to periodontal destruction in the vicinity of the gingival microvasculature. 
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Table 7. Effect of smoking on GCF content of some biomarkers in periodontitis or in experimental 
gingivitis*. Biomarker Effect in GCF Reference 
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Söder 1999  
 




Persson et al. 2001 
 
Persson et al. 2001 
 




Söder 1999 / Söder et al. 2002 
 
Boström et al. 1998a, b, 1999 
 
Giannopoulou et al. 2003a 
Giannopoulou et al. 2003b 
 
Erdemir et al. 2004;  
Boström et al. 1999 
Giannopoulou et al. 2003b 
 
Giannopoulou et al. 2003a 
Giannopoulou et al. 2003b 
 
Goutoudi et al. 2004 
 
Boström et al. 2000; Giannopoulou et 
al. 2003b; Goutoudi et al. 2004 
 
 
Rawlinson et al. 2003 / Boström et al. 
2000 
 
Petropoulos et al. 2004 
 
Fraser et al. 2001 
 
Boström et al. 2000 
 
 
Al-Shammari et al. 2001 
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5.8. SALIVA AND ORAL RINSES IN PERIODONTAL DIAGNOSTICS 
 
Saliva may offer potential as a periodontal diagnostic aid at the patient level, and for this 
purpose it has been a subject of much research activity. Saliva can easily be collected as 
whole saliva or from specific salivary glands with or without gustatory stimulation. Whole 
saliva is a mixture of oral fluids: it contains secretions of the minor and major salivary glands 
as well as GCF, excreted bronchial secretions, serum and blood cells from oral wounds, 
micro-organisms and desquamated oral epithelial cells and food debris (Kaufman and 
Lamster 2000). Salivary-based caries susceptibility tests have been relatively well established 
(Mandel 1993). Whole saliva holds promise for periodontal diagnostics because it contains 
locally delivered and systematically-derived markers of periodontal disease derived from 
GCF of all teeth. Periodontal treatment reduces salivary enzyme levels, and salivary enzyme 
levels have been proposed as a means to monitor the effectiveness of periodontal treatment 
(Zambon et al. 1985). 
 
Aminopeptidase enzyme activity in mixed whole saliva is significantly higher in LJP and 
AP patients compared to healthy controls (Nakamura and Slots 1983; Gregory et al. 1992). 
AP patients demonstrate higher levels of salivary collagenase and elastase-like activity 
when compared with LJP patients and healthy controls (Uitto et al. 1990; Ingman et al. 
1993). Very little collagenase activity was found in whole saliva of edentulous subjects 
suggesting that most of the collagenase in saliva is derived from neutrophil cells entering the 
oral cavity through the gingival crevice (Sorsa et al. 1990; Uitto et al. 1990). Most of the 
periodontitis patients’ salivary collagenase is in an active form and in periodontally healthy 
subjects in a latent form (Uitto et al. 1990; Hayakawa et al. 1994). Total TIMP-1 in 
periodontitis patients’ whole saliva seems to be lower than in healthy subjects (Hayakawa et 
al. 1994). 
 
Periodontal therapy resulted in reduced collagenase and elastase activities in chronic 
periodontitis and LJP patients’ saliva (Gangbar et al. 1990; Uitto et al. 1990; Ingman et al. 
1993) as well as in adult periodontitis patients’ oral fluid (Uitto et al. 1996). Salivary elastase 
was found to correlate significantly with the number of deep periodontal pockets and the 
percent of bleeding sites (Nieminen et al. 1993). There is also a finding that S periodontitis  
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patients had significantly lower salivary elastase levels than former S or NS periodontitis 
patients and less neutrophils in saliva than NS patients (Pauletto et al. 2000). 
 
Also, salivary proteolytic activity and MMP-8 levels were lower in current smokers than in 
former smokers but there was no difference in BOP. It was concluded that the use of 
salivary/mouthrinse proteinases as diagnostic markers of periodontal disease activity should 
be done with caution (Liede et al. 1999). High MMP-9 (92 kDa gelatinase) levels were 
detected in periodontitis patients’ whole saliva compared with healthy subjects (Mäkelä et al. 
1994). 
 
Also salivary MPO activity has been suggested to have a relationship to the severity of 
periodontal disease, while increased MPO activity has been detected in saliva of patients with 
rapidly progressing periodontitis (Over et al. 1993). Lower levels of lysozyme has been 
reported in periodontitis patients’ saliva compared with healthy controls (Markkanen et al. 
1986) and increased peroxidase activity in experimentally induced gingival inflammation 
(Smith et al. 1984). However, lactoferrin concentrations in chronic periodontitis patients’ 
stimulated and unstimulated whole saliva and GCF were reduced significantly after 
periodontal surgery, whilst no change in salivary peroxidase or lysozyme could be detected 
(Jentsch et al. 2004). 
 
From plasma cells in the salivary glands secretory IgA is the main specific immune 
mechanism of saliva. IgG is present in low concentrations in saliva and primarily derived 
from serum via GCF. Studies evaluating the presence of total and specific immunoglobulin 
directed against periodontal pathogens in saliva have aimed to determine their relationship to 
periodontal status. Higher levels of IgA have been detected in whole saliva of patients with 
gingivitis or periodontitis than in healthy subjects (Guven et al. 1982) but also a 
contradictory finding exists (Bokor 1997). Reductions in salivary IgA and IgG levels proved 
to be an indicator of periodontal treatment response (Reiff 1984), but in another study only 
IgG salivary concentration was elevated in untreated periodontal patients compared to post-
treatment levels (Basu et al. 1976). 
 
Specific immunoglobulins against periodontal pathogens hold more promise than assessment 
of non-specific immunoglobulin isotypes. Longitudinal studies support the potential of 
characterising specific salivary immunoglobulins as markers of periodontal disease activity 
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(Sahingur and Cohen 2004). Purified antigen preparations are suggested to give better 
sensitivity and specificity of antibody-based diagnostics because of reduced non-specific 
cross-reactivity with non-oral bacteria which share common epitopes with 
periodontopathogens (Offenbacher et al. 1993). Significantly higher concentrations of 
salivary IgG were found both in patients with AP and with JP towards A. 
actinomycetemcomitans but salivary IgA was not influenced by periodontal status (Sandholm 
et al. 1987). In addition to IgG, IgA specific against A. actinomycetemcomitans correlated 
significantly with corresponding antibody titers in the serum (Nieminen et al. 1993). 
 
Saliva has been studied and proposed also as a potential media for detection of oral bacteria 
because of its non-invasive sampling (Kaufman and Lamster 2000). However, salivary 
analysis is mainly a research tool because of the lack of uniform data which supports the 
periodontal diagnostic value of salivary testing. Also it is not known how various general 
diseases such as HIV may affect values of salivary/oral rinse biomarkers for periodontal 
diseases (Mellanen et al. 1996, 1998). Furthermore, the effects of systemic medication of 
proteinase inhibitors such as doxycycline and bisphosphonates can be monitored successfully 
from saliva by zymography, collagenase activity assay, MMP-immunoassays and specific 
peptide activity assays for MMPs (Lauhio et al. 1994a, b, 1995; Nordström et al. 1998; 
Valleala et al. 2000; Fingleton et al. 2004). 
 
5.9. DETECTION METHODS FOR GCF BIOMARKERS 
 
5.9.1. Laboratory methods for GCF biomarker detection 
 
The presence of proteolytic enzymes in GCF has been measured by immunological assays 
such as enzyme-linked immunosorbent assay (ELISA) (Ingman et al. 1996) and 
immunoblotting (Sorsa et al. 1994, 2004a, b; Kiili et al. 2002), both of these using high-
affinity antibodies to recognise the given enzyme. Immunoblotting used with 
chemoluminescence is a capable and sensitive method for the estimation of molecular forms 
and mass of the enzyme of interest, but it is not very useful for quantitative analyses. 
ELISA/IFMA-methods can be used to test multiple markers and their levels in single 
samples. Two different antibodies are used: one for capturing the soluble enzyme and the 
other to detect the captured enzyme. 
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Substrate assays measure primarily the ability of the enzyme to degrade the substrate, and 
the enzyme activity will be estimated by different methods like gelatine enzymography 
(Gangbar et al. 1990), release of radioactivity from radiolabelled collagen fibrils (Villela et 
al. 1987), and fluorogenic assays based on synthetic peptides that mimic the cleavage site of 
collagenase (Knight et al. 1992; McCulloch 1994a, b). The degradation of the collagen in 
solution can be analysed by radiolabelled substrate assay SDS-PAGE fluorography (Larivee 
et al. 1986; Overall and Sodek 1987; Lee et al. 1991). This method needs seven days to be 
completed and it uses radioactivity and thus is unsuitable for clinical use. 
 
The direct measurement of collagen or laminin-5 gamma2-chain break-down products in 
GCF and PISF has also been used as an analytical approach (Talonpoika and Hämäläinen 
1994; Golub et al. 1997; Kivelä-Rajamäki et al. 2003; Emingil et al. 2004b, 2006b). A test 
based on biotinylation of collagen and the assay of labelled degradation products (soluble 
biotinylated collagen assay) can detect collagen and its labelled degradation products, and it 
was shown to be sensitive and reproducible in detection of protease activity in highly diluted 
mouthrinse samples (Mancini et al. 1999). Laminin-5 gamma2-chain fragments in GCF and 
PISF have been suggested to reflect active phase of periodontal and peri-implant 
inflammation (Kivelä-Rajamäki et al. 2003b; Emingil et al. 2004b, 2006b). 
 
All of these methods are sensitive and specific and suitable to quantify collagenolytic 
enzymes/MMPs in microliter samples but all of them are time-consuming and not practical 
for routine clinical use. 
 
5.9.2. Periodontal test kits 
 
A number of test kits for the detection of GCF biomarkers by different methods or for the 
detection of certain periodontopathogens by an enzymatic reaction have been developed for 
commercial use or as a prototype test. In the following section the studies evaluating these 
tests are reviewed. However, with the available information (Internet) these tests, with the 
exception of BANA-test, are no longer available or not developed further from the prototype 
version. 
 
A commercial test kit for measuring AST activity from GCF, PerioGard™ (Xytronyx, Inc., 
San Diego, CA), was designed to give a positive test score with GCF AST activity ≥ 800 
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µl/U. The test kit consisted of a tray with two test wells for the sample from each tooth and 
the reagents for conducting the test. The test result could be read by eye comparing the test 
colour to the positive control in 15 min. In a cross-sectional study the percentage of 
PerioGard™-positive sites decreased significantly between the baseline and post-treatment 
visits (Persson et al. 1995). With the same study design it was regarded to be an objective 
measure to distinguish between diseased and non-diseased sites and in monitoring the 
outcome of therapy (Magnusson et al. 1996). The predictive value of this test is unknown 
while the results of the longitudinal part of this multi-centre study have not been published. 
 
Kamma et al. (2001b) found a high level of agreement between the periodontopathogens 
(Streptococcus intermedius, Peptostreptococcus micros, B. forsythus, P. gingivalis, 
Campylobacter rectus, Selenomonas sputigena) and positive AST test results (PerioGard™) 
at periodontal sites that were clinically considered potentially disease active. A kit based on 
same principle to measure GCF AST (Perimonitor™, Hawe Neos Dental, Switzerland) has 
been tested in a cross-sectional study, where positive test result correlated with gingival 
index (GI) but not with PD both in diabetic and non-diabetic patients suffering of chronic 
periodontitis (Yucekal-Tuncer et al. 2003). The same finding has been done in a study by 
Smith et al. (1998) where a positive AST test result (PerioGard™) correlated with GI but not 
with PD. 
 
The third test based on the same principle: PocketWatch™ (Pacific Pharmaceuticals Inc., San 
Diego, CA), has been evaluated in a treatment study by Shimada et al. (2000). They 
concluded that AST levels monitored with this test may be a useful adjunct in the clinical 
assessment of periodontal disease sites though previously they found that the coefficients 
were too small to show a definite relationship between AST levels measured with 
PocketWatch™ and clinical periodontal status (Shimada et al. 1999). Barbosa et al. (2003) 
suggested that more research should be carried out to evaluate the true relationship between 
AST and periodontal disease because they found no correlation between GCF AST 
diagnosed with PocketWatch™ and the clinical parameters. In a 12-month longitudinal study 
the testing of GCF AST with PocketWatch™ chair-side assay in monitoring periodontal 
disease activity was associated with many false positive results, but a high negative 
predictive value was indicative of a periodontally stable site (Oringer et al. 2001). Elevated 
AST levels and test positive sites were present due to gingival inflammation with no disease 
 58
progression which diminishing the tests ability to discriminate between progressive and 
inflamed stable sites (Kuru et al. 1999). 
 
A trypsin-like enzyme possessed by periodontopathogenic bacteria B. forsythus, Treponema 
denticola and P. gingivalis can be detected by an enzymatic assay where the substrate N-
benzoyl-DL-arginine-2-naphthylamine (BANA) present on the test strips breaks down and 
produces a colour effect whose intensity is in proportion to the total amount of these 
microbial species (Loesche et al. 1990; Bretz et al. 1990). The BANA test requires a plaque 
sample from periodontal pockets. BANA hydrolysis has been shown to correlate well with 
PD in periodontitis sites (Grisi et al. 1998; Smith et al. 1998; Yucekal-Tuncer et al. 2003) 
but not with GI (Smith et al. 1998; Yucekal-Tuncer et al. 2003), and it’s reliability to predict 
disease progression is weak (Hemmings et al. 1997). Loesche et al. have investigated BANA 
testing in monitoring the effect of systemic metronidazole in reducing spirochetes from deep 
periodontal pocket (1990) and in identifying the non-compliant patient with the usage of 
prescribed medication (1993), and found the test to be useful for these purposes. In a 
treatment study of chronic periodontitis patients with moderate to severe disease the BANA 
test Perioscan™ had a baseline sensitivity of 99% and specificity of 55% when related to 
clinical diagnosis. The probability of the test to agree with the clinical treatment outcome 
was calculated as 52%, leading to the conclusion that this diagnostic kit does not reliably 
reflect the clinical assessment of periodontal disease in cross sectional study or the treatment 
outcome (Hemmings et al. 1997). However, human/host-cell derived trypsin-like proteinases 
can easily degrade the BANA-substrate (Ingman 1994). 
 
Hemmings et al. (1997) compared the Periocheck™ kit (a colorimetric assay for the presence 
of non-specific neutral proteases and elevated levels of proteolytic activity in GCF) with 
clinical methods. Baseline sensitivity for Periocheck™ was 88% and specificity 61% when 
related to clinical diagnosis, and the probability for agreement with the clinical treatment 
outcome was 50.4% thus not reliably reflecting the clinical assessment of periodontal 
disease. In an earlier study the highest percentage (33%) of elevated protease activity was 
found in patients clinically diagnosed as having advanced periodontal disease and the assay 
was reproducible with 98.6% in sites remaining stable with a 3-day testing interval (Bowers 
and Zahradnik 1989). After therapy, the neutral proteinase assay score decreased and the 
clinical parameters improved. However, the predictive value of neutral protease testing has 
not been evaluated in a longitudinal trial. 
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A prototype test kit for analysing GCF elastase has been evaluated in a longitudinal study 
(Palcanis et al. 1992; Armitage et al. 1994). After 15 s collection of GCF the test strip, 
impregnated with a human neutrophil elastase substrate is placed into an ultraviolet viewing 
box for visual assessment of the intensity of fluorescence, which is relative to elastase 
activity of the sample and scaled from 0 to 4 using intensity standards as a guide. In the 
earlier of these two studies visual interpretation of fluorescence in a strip was found to 
represent enzyme activity in GCF which presumably was related to biological changes 
occurring in the periodontal tissues site specifically (Palcanis et al. 1992). This VES (visual 
elastase scores) test gave a relatively low number of false negatives, but it failed as a 
discriminatory prognostic test because of its high percentage of false positives (Armitage et 
al. 1994). It was concluded that the VES test may, however, be of some advantage when used 
in conjunction with traditional assessments of periodontal disease. 
 
5.9.3. Tests for genetic risk factors 
 
Environmental exposures explain only in part the variability in susceptibility to periodontal 
diseases between individuals and part of the variation can be explained by genetic 
background (Michalowics 1994). Excess in pro-inflammatory cytokine production can lead 
to periodontal destruction at the site of bacterial plaque. Individuals with susceptibility to 
periodontal destruction have overactive monocytes which produce, when triggered by the 
presence of bacterial biofilm, pathologically excessive amounts of cytokines (Champagne et 
al. 2003). Individuals with a special IL-1ß genotype are found out to be more susceptible to 
develop periodontitis (Kornman et al. 1997b). Based on this discovery a blood test has been 
developed to determine the IL-1 genotype. Other candidate genes with a possible association 
to chronic periodontitis include for example TNFα polymorphism, human leucosyte antigens 
(HLA), and FcγR genotypes (Goteiner and Goldman 1984; Kobayashi et al. 1997; Galbraith 
et al. 1998). However, there can be several other factors which may contribute to individual 
susceptibility, and at the moment no specific genetic test can predict the development of 
periodontitis or the outcome of periodontal treatment. 
 
Based on the studies of IL-1 gene cluster the Periodontal Susceptibility Test® (PST®), only 
commercially available genetic susceptibility test, has been developed. The PST® test 
evaluates the simultaneous occurrence of allele 2 at two different loci. When a patient is 
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diagnosed to have allele 2 in both of these loci, she/he is considered to be genotype-positive 
and produce more IL-1 in response to bacterial challenge. An IL-1 response predisposes to 
more inflammation and tissue destruction (Kornman et al. 1997b; Engebretson et al. 1999) 
and an individual is more susceptible to develop chronic periodontitis. The original finding 
was that among NS periodontitis patients, the composite phenotype was more frequent when 
compared to controls (Kornman et al. 1997b). The odds of being genotype positive were 6.8 
times higher among severe periodontitis patients than among controls with mild or no 
disease. When smokers were included in the study the association became insignificant. 
 
Later there have been studies that do not support association between IL-1 genotype and 
periodontitis (Mark et al. 2000) or inconsistencies with an association to periodontitis (Gore 
et al. 1998). Lack of consistency (Diehl et al. 1999; Parkhill et al. 2000) or no association 
(Hodge et al. 2001) has also been observed in studies of aggressive periodontitis leading to 
questions about the clinical applicability of the PST® test. Genotype-negative periodontitis 
patients have been reported (Kornman et al. 1997b; Cattabriga et al. 2001; Papapanou et al. 
2001), and healthy periodontium or mild disease in genotype-positive patients has also been 
reported (Kornman et al. 1997b; Walker et al. 2000). Also, great racial variability exists in 
the prevalence of the composite IL-1 genotype (Kornman et al. 1997b; Gore et al. 1998; 
Armitage et al. 2000; Caffesse et al. 2002a). In predicting the outcomes of periodontal 
treatment (Ehmke et al. 1999; De Sanctis and Zucchelli 2000; Caffesse et al. 2002b) or 
implant failures (Wilson and Nunn 1999; Rogers et al. 2002) the PST® test was not accurate 
but there is debate about applicability of the test in predicting long-term stability during 
maintenance (McGuire and Nunn 1999; De Sanctis and Zucchelli 2000; Lang et al. 2000; 
Cattabriga et al. 2001). 
 
5.9.4. Equipments for periodontal diagnosis 
 
For the measurement of subgingival temperature ABIO-DENT (Danvers, MA) developed a 
Periotemp® thermal probe for the risk assessments of the early stages of periodontal disease. 
Haffajee et al. (1992a) measured baseline subgingival temperature and found that the deeper 
the pocket the higher the subgingival temperature was and correlated positively with plaque, 
gingival redness, BOP and CAL. In a longitudinal study it was found that an elevated 
subgingival temperature was related to subsequent attachment loss particularly in patients 
who exhibited several progressing sites (Haffajee et al. 1992b). Rams et al. (1993) postulated 
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that dental implant status can be monitored by sulcular temperature. The Periotemp® can 
also be used to evaluate the parameter from all sites of dentition. Nevertheless, the 
temperature probe has not been widely utilised in the periodontal clinic. 
 
The Reflotron® System of Diagnosis is largely used in medicine in clinical laboratories to 
diagnose damage of the heart and liver by determining clinical-chemical parameters from 
capillary or venous blood, heparinised plasma and serum (Schuman et al. 2001). Cesco et al. 
(2003) studied using the Reflotron® the relationship between salivary AST levels and 
periodontal disease indicated by the community periodontal index of treatment needs 
(CPITN). Patients with CPITN 4 could be detected with this diagnostic system and 
periodontal destruction seems to be related to higher salivary AST levels. 
 
Volatile sulphur compounds, such as hydrogen sulphide and methyl mercaptan, are toxic 
metabolites of periodontopathogens, and their role in periodontal disease is still poorly 
understood. The Diamond Probe / Perio 2000 System® (Diamond General Development 
Corp., Ann Arbor, MI) is a periodontal disease evaluation system to detect GCF sulphide 
concentration in various forms as an indicator of gram-negative bacterial activity. The system 
combines a Michigan dental probe with a sulphide sensor, and it measures PD, BOP and 
sulphide simultaneously (Zhou et al. 2004). Morita and Wang (2001) found in their study 
with chronic periodontitis patients that sulcular sulphide detected by using Diamond Probe / 
Perio 2000 correlated positively with the BANA test and may be an indicator of active 
periodontal disease. The same device was used by Zhou et al. (2004) in an experimental 
gingivitis study, and the results indicated that detection of sulphur was the first parameter to 
show plaque-induced gingivitis. Gleissner et al. (2002) regarded the sulphide monitor a 
reliable method and a valuable supplement to traditional clinical examination methods: no 
sulphide was detected in healthy controls while sulphide correlated significantly with PD in 
gingivitis, with CAL and PD in periodontitis, and with BOP. 
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6 AIMS OF THE STUDY 
 
During periodontitis, tooth-supporting tissues (the gingiva, periodontal ligament, root 
cementum, and alveolar bone) undergo irreversible destruction which is primarily carried out 
by the inflammatory host response raised by the subgingival microflora. Periodontal 
destruction is considered to be episodic in nature with great individual variation in respect to 
the destruction pattern. This is rather difficult to diagnose with traditional clinical methods. 
Long-term treatment and prevention should be based on etiopathogenic factors, and for this 
purpose biochemical methods and markers may prove to be crucial. 
 
The aims of this study were: 
1. To assess the association of matrix metalloproteinase (MMP) -8 in GCF with 
periodontal disease (I) and to assess GCF MMP-8 levels during periodontal treatment 
and maintenance (III). 
2. To develop a MMP-8 specific chair-side dip-stick test for identifying and monitoring 
the course and treatment of periodontitis (II). 
3. To evaluate the value of GCF MMP-8 chair-side testing and the assessment of MMP-
8 GCF levels with an immunofluorometric assay in monitoring treatment response 
and in identifying sites at risk of progression of periodontitis during the maintenance 
phase in chronic periodontitis patients (IV, V). 
4. To evaluate the effect of smoking on GCF MMP-8 levels and chair-side test results 
(V). 
5. To determine whether Chlamydia pneumoniae is localised in the periodontitis 
patients’ deep periodontal pockets and its relation to GCF MMP-8 levels because C. 
pneumoniae is not normally associated with the periodontitis (VI). 
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7 MATERIALS AND METHODS 
 
Detailed methods are described in the original publications I—VI. 
 
7.1. Study populations and samples 
 
Thirteen untreated chronic adult periodontitis patients participated in study I. GCF samples 
were collected for analysis of MMP-8 levels and elastase activities. Clinical parameters were 
recorded at baseline and two weeks after the completion of periodontal treatment (oral 
hygiene instructions and scaling and root planing, SRP). 
 
In study III 20 untreated chronic adult periodontitis patients were recruited. GCF samples 
were collected from four sites in each subject with a pocket depth ≥ 5 mm for analysis of 
MMP-8 concentrations and clinical parameters. Recordings were done at baseline, after SRP 
and after a three month maintenance phase. 
 
In study IV GCF samples were collected for MMP-8 concentration analysis and tested with a 
MMP-8 specific chair-side dip-stick test, and clinical parameters were recorded at baseline 
and after SRP from 11 untreated adult chronic periodontitis patients (90 sites), and once from 
10 patients with gingivitis (58 sites) and from eight periodontally healthy controls (59 sites). 
 
In study V 16 untreated chronic periodontitis patients participated in the cross-sectional 
treatment study [initial treatment response; baseline—post SRP; 11 smokers (S; 89 sites) and 
5 non-smokers (NS; 43 sites)], and 15 of them [10 S patients (80 sites) and 5 NS patients (43 
sites) were followed-up bimonthly during a 12 month maintenance phase (post SRP—12 
months). At each visit GCF samples were collected from the same pre-selected sites for 
MMP-8 concentration analysis. Samples were tested with a MMP-8 specific chair-side dip-
stick test and clinical parameters were recorded. 
 
In study VI subgingival plaque samples were collected from 31 teeth of 12 adult chronic 
periodontitis patients. GCF samples for analysis of MMP-8 concentration were collected and 
clinical parameters were recorded. All samples and recordings were performed at baseline 
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and after SRP. Plaque samples from different pockets per patient were pooled to give one 
sample (Nieminen et al. 1995; Mellanen et al. 1996). 
 
All periodontitis patients fulfilled the following criteria: 1) no history of systemic disorders, 
2) no history of antibiotics and/or anti-inflammatory drugs within the past 6 months, 3) no 
history of any periodontitis treatment within the past 6 months, 4) the presence of at least 20 
teeth, and 5) at least 5 sites exhibiting ≥ 4 mm probing depth and radiographic bone loss. 
 
Gingivitis patients comprised cases with GI 2—4 and PD ≤ 3 mm. Periodontally healthy 
individuals had GI of 0 or 1 and PD ≤ 2 mm. 
 
Approvals for the studies were provided by the Ethics Committee of the Institute of 
Dentistry, University of Helsinki, by the Ethics Committee of Glasgow Dental Hospital and 
School, and by King’s Healthcare, London, United Kingdom. All patients gave informed 
consent for participation. 
 
7.1.1. GCF and subgingival plaque sampling and clinical measurements 
 
Prior to GCF sampling the crown of the tooth was gently cleaned to remove supragingival 
plaque, dried and isolated with cotton rolls to exclude contamination with saliva. The tip of a 
filter-paper sampling strip for absorbing GCF was placed into the gingival sulcus for 30 s 
avoiding any bleeding from the marginal gingiva, and removed into a test tube containing 
buffer solution (I, III, IV—VI). In studies I and III the volume of GCF was determined using a 
Periotron 6000. 
 
For subgingival plaque sampling, supragingival plaque was removed from the teeth with a 
curette, gingival margins were dried with air and isolated from saliva with cotton rolls, and 
subgingival plaque samples were collected with sterile curettes. All samples of subgingival 
plaque were pooled to give one sample per patient (VI). 
 
In studies I, IV and VI pocket depth (PD), bleeding on probing (BOP), gingival index (GI), 
and plaque index (PI) were recorded, in study III PD, BOP, PI, attachment loss (AL), 
suppuration (Supp), and modified gingival index (MGI), and in study V PD, AL and BOP. In  
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study III PD and AL measurements were done using the Florida probe with pocket depth and 
disc probes, respectively. In studies I, IV, V and VI clinical measurements were done with a 
manual probe. 
 
The timeline and the site groups in study V are shown in Figure 3. Sites with an AL increase 
≥ 2 mm during the maintenance phase (post SRP—12 months) were regarded as progressing 
sites and sites with repeatedly and exceptionally elevated MMP-8 concentrations (≥ 4000 
µg/l two or more times during the maintenance phase) as high-responder sites (V). All but 
one of high-responder sites were smokers’ sites. Therefore we examined smokers’ sites 




Figure 3. Groups and timeline of the longitudinal maintenance phase study. 
 
7.2. MMP-8 SPECIFIC CHAIR-SIDE DIP-STICK TEST 
 
Study II introduces the principle of the immunochromatocraphic MMP-8 specific chair-side 
dip-stick test. 
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7.2.1. Principle of the test 
 
The MMP-8 test stick is based on the immunochromatography principle and it involves two 
monoclonal antibodies specific for different epitopes of MMP-8 (Hanemaaijer et al. 1997). 
Antibody 1 is bound to blue latex particles which act as the detecting label, and are dried next 
to the dip area of the dipstick. The other antibody is immobilised on a carrier membrane to 
catch labelled particles and to indicate a positive result (Figure 4). When the dip area of the 
test stick is placed in an extracted GCF sample, the dipstick absorbs liquid which flows up 
the nitrocellulose membrane. If the sample contains MMP-8 it binds to the antibody attached 
to the latex particles, and the particles are carried by the liquid flow along the test stick over 
the catching zone containing the other MMP-8 antibody. If the concentration of MMP-8 in 
the sample exceeds the cut-off value for the test (1000 µg/l), a blue line will appear to 
indicate a positive result. The test is designed to give a detection limit of 1000 µg/l based on 
earlier studies on MMP-8 in GCF collected from periodontitis and gingivitis patients’ sites 
and from periodontally healthy individuals’ sites. A second blue line confirms the correct 
performance of the test. 
 
 
Figure 4. Principle of the MMP-8 specific chair-side test based on immunochromatography involving 
two monoclonal antibodies. 
2 
Immobilized anti-MMP-8 
Sample Latex particles coated with anti-MMP-8 
Anti-mouse 
immunoglobulin 
Migration of the sample 
1 
3 Positive result Control line
4 Negative result 
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7.2.2. Chair-side procedure with the MMP-8 specific dipstick test 
 
GCF sampling is described in chapter 7.1.1. After removal from the gingival sulcus, the 
sampling strip is placed for elution of the specimen proteins into a test tube containing 0.5 ml 
of HEPES-buffer, pH 7.4, for 5 min. The tip of an MMP-8 dipstick is then immersed in the 
buffer for about 10 s, removed and left for 5 min. The test is positive if the blue line appears 
(Figure 5). Positive test results were registered as: + (weak blue line), ++ (clear blue line), or 
+++ (strong blue line). 
 
 
Figure 5. Test positive result of the MMP-8 specific chair-side dipstick test (left) is confirmed with 
the appearance of the blue line in the catching zone. 
7.3. MMP-8 IMMUNOFLUOROMETRIC ASSAY (IFMA) 
 
The concentration of the monoclonal MMP-8 of GCF was determined by a time-resolved 
immunofluorescense assay (IFMA) as described by Hanemaaijer et al. (1997). The 
monoclonal MMP-8-specific antibodies 8708 and 8706 were used as a catching antibody and 
a tracer antibody, respectively. The tracer antibody was labelled using europium-chelate 
(Hemmilä et al. 1984). The assay buffer contained 20 mM Tris-HCl (pH 7.5), 0.5 M NaCl, 5 
mM CaCl2, 50 µM ZnCl2, 0.5% bovine serum albumin, 0.05% sodium azide, and 20 mg/litre 
DTPA. Samples were diluted in assay buffer and incubated for 1 h, followed by incubation 
for 1 h with tracer antibody. Enhancement solution was added, and after 5 min fluorescence 
was measured using 1234 Delfia Research Fluorometer (Wallac, Turku, Finland). The 
monoclonal MMP-8 antibody specificity corresponded to that of the polyclonal MMP-8 
antibody (Hanemaaijer et al. 1997). 
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7.4. ELASTASE ACTIVITY ASSAY 
 
GCF eluates were assessed for elastase activity against the fluorogenic substrate MeOSuc-
Ala-Ala-Pro-Val-AFC by a fluorometric assay (Cox and Eley 1992). Eluates were added to 
0.1 M assay buffer containing 0.1% v/v Triton X-100 and then the reactions started by the 
addition of substrate to give a final concentration of 10 µM in a volume of 2.0 ml. The 
concentration of liberated AFC was measured after 5 hours using a fluorostat calibrated with 
AFC. Total activities of strips were expressed in terms of µUnits (pmols of substrate 
hydrolysed per min). Enzyme activities were calculated relative to the corresponding 
volumes of GCF. 
 
7.5. SUBGINGIVAL PLAQUE SAMPLE ANALYSIS FOR DETECTION OF CHLAMYDIA 
PNEUMONIAE 
 
Subgingival plaque samples were examined for Chlamydia pneumoniae by means of PCR. 
DNA analyses were undertaken on the samples by means of the QIAamp DNA Mini Kit® 
(Qiagen, Germany), following the instructions of the manufacturer. A hot-start technique was 
used with C. pneumoniae OMP 1 gene probes. Europium-labelled probes were used in 
hybridization of PCR products. Counts of 50 000 or over were regarded as positive, counts of 
less than 50 000 as negative (Rintamäki et al. 2001). 
 
7.6. STATISTICAL ANALYSES 
 
Because of the skewed nature of the data, non-parametric tests were used. Comparisons of 
clinical parameters and concentrations of MMP-8 in GCF in various conditions were 
performed with the Mann-Whitney U-test (IV, V). The comparisons of clinical parameters 
and MMP-8 and elastase concentrations and elastase activities in the GCF samples before 
and after SRP were performed with the Wilcoxon matched pair’s test (I, III, IV, V). 
Longitudinal comparisons of MMP-8 concentrations between different groups were analysed 
with one-way ANOVA after logarithmic transformation. In all comparisons the level of 
statistical significance was set at p < 0.05. Agreement between the quantitative determination 
of MMP-8 and the test stick result was estimated with the Kappa statistic (< 0.20 indicates 




8.1. MMP-8 CONCENTRATIONS IN GCF 
 
MMP-8 levels in GCF dropped following initial periodontal treatment (I, III, IV, V, VI) and 
reduced still further by 50% compared with the post SRP situation once the wound healing 
phase of tissues was over (III). 
 
In the cross-sectional study (IV) the median MMP-8 concentration in periodontally healthy 
subjects’ GCF was 100 µg/l (interquartal percentile 40 µg/l, 170 µg/l), in gingivitis patients’ 
GCF 470 µg/l (interquartale percentile 130 µg/l, 929 µg/l) and in adult periodontitis patients’ 
GCF before treatment (SRP) 1850 µg/l (interquartale percentile 820 µg/l, 4290 µg/l). The 
difference between all conditions was statistically significant (p < 0.001). After treatment the 
MMP-8 concentration in the periodontitis patients’ GCF decreased statistically significantly 
(median 970 µg/l, interquartale percentile 470 µg/l, 2220 mg/l; p < 0.001) but remained at a 
higher level than in periodontally healthy or gingivitis subjects’ GCF. 
 
The highest baseline GCF MMP-8 concentrations were in samples from periodontal pockets 
with PD > 5 mm and which were BOP positive (median 4300 µg/l, interquartale percentile 
2600 µg/l, 6200 µg/l). Also in these sites SRP decreased MMP-8 concentrations significantly 
(median 1500 µg/l, interquartale percentile 480 µg/l, 3100 µg/l; p < 0.001) (IV). 
 
8.1.2. Comparison of MMP-8 levels in smokers’ and non-smokers’ GCF (V) 
 
The timepoints of GCF sampling and clinical measurements of the study are represented in 
Figure 3. In the longitudinal study (V) smokers’ (S) sites (n = 80) and non-smokers’ (NS) 
sites (n = 43) were analysed separately. In S sites the mean GCF MMP-8 concentration at 
baseline was significantly lower than in NS sites (p < 0.001). In S sites decrease of mean 
concentration after treatment (SRP) was not significant (baseline 1268 µg/l, after SRP 975 
µg/l; p = 0.7) but significant in NS sites (baseline 3997 µg/l, post SRP 2076 µg/l; p < 0.001). 
 
S and NS sites were further grouped according to the status at the end of the maintenance 
phase (V): S and NS sites with an attachment loss increase of ≥ 2 mm were regarded as 
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progressing sites and other sites as stable sites. 12% of NS sites (n = 5) and 20% of S sites (n 
= 16) were thus categorised as progressing sites. When progressing S sites and stable S sites 
were compared, the difference between mean MMP-8 concentrations was not significant at 
baseline, after SRP or at any maintenance visits, and in neither group of S sites SRP 
decreased mean MMP-8 concentration statistically significantly. However, in progressing S 
sites the distribution was, for every measurement, broader than in stable sites showing a 
tendency towards elevated MMP-8 levels. MMP-8 levels in progressing S sites were 
comparable with MMP-8 levels in progressing NS sites. 
 
Sites with a MMP-8 concentration ≥ 4000 µg/l at two or more measurements during the 12 
month maintenance phase were extracted from the data and analysed. Sites filling this 
criterion were eight S sites reaching exceptionally high MMP-8 levels (high-responder S 
sites; n = 8). These S sites concentrated into two patients, and five out of these eight sites 
were sites which also were categorised as progressing sites. 
 
When high-responder S sites were compared with S sites with lower concentrations (low-
responder S sites; n = 72), no significant difference in mean MMP-8 concentrations at 
baseline, post SRP and at 2-month measurement could be observed, but in high-responder 
sites the distribution was broader at these measurements. At 4—12-month maintenance phase 
measurements, difference between MMP-8 concentrations of these two groups of S sites 
were statistically significant. 
 
8.2. MMP-8 CHAIR-SIDE TESTING 
 
For a positive test-stick result the threshold for MMP-8 concentration was set at 1000 µg/l, 
and test results of individual sites were registered as follows: + (weak blue line), ++ (clear 
blue line) and +++ (strong blue line) (IV, V). 
 
In the cross-sectional study IV the test stick result was well in unison with the quantitative 
MMP-8 analysis (IFMA) of the GCF samples (Figure 6). Only 18 of the 207 tested sites 
were in discrepancy. Thus the agreement was very good when calculated with the Kappa 
statistics (κ = 0.81), and the chair-side test provided a sensitivity of 0.83 and specificity of 
0.96. The test-stick result also correlated well with the periodontal status of the above 
mentioned three groups. Only with few exceptions test results in healthy individuals’ sites or 
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gingivitis patients’ sites were negative. However, test result was most prone to be false 
negative or false positive near the concentrations of the cut-off threshold value 1000 µg/l 
(Figure 6) (IV). 
 
 
Figure 6. Scattergram of periodontitis patients’ sites (n = 132) at baseline: correlation of MMP-8 
concentration (IFMA µg/l) and MMP-8 specific chair-side dipstick test result (0 = negative, 1 = +, 2 = 
++, 3 = +++) (Mäntylä et al., to be published, 2006). 
 
In the data processing of the longitudinal maintenance phase study (V) positive test results 
were expressed in two ways: all positive results + — +++ / clear test positive results ++ — 
+++. Percentages for respective test results were calculated. At the baseline measurement of 
the longitudinal study the MMP-8 chair-side dip-stick test result was positive in 50 % of sites 
when all positive test results were calculate and in 27% of sites when clear test positive 
results were calculated. After SRP the percentages were 39 and 10 respectively (n = 123) (p 
< 0.05). 
 
Test result was more often positive at baseline in all NS sites (n = 43) and in progressing NS 
sites (n = 5) than in respective S sites (all S sites n = 80, progressing S sites n = 16). Test 
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positive percentages in NS sites decreased after treatment statistically significantly (p < 
0.001). For all S sites the difference between baseline and post SRP test positive percentages 
was not statistically significant. In progressing S sites the percentage of test positive sites 
increased after SRP thus reaching proportion of NS sites which were test positive (V). 
 
In high-responder S sites (n = 8) the baseline test positive percentages reacted poorly to SRP. 
In this group of sites higher test positive percentages were seen at the majority of 
measurement points during the maintenance phase than in low-responder S sites (n = 72) (V). 
 
Based on test results of high- and low-responder S sites during the maintenance phase, 
sensitivity and specificity were calculated. Values were respectively 0.41 and 0.91. 
 
8.3. BLEEDING ON PROBING SCORES 
 
General BOP positive scores decreased after SRP when the smoking status was ignored (I, 
III, IV, V). Periodontitis patients’ deepest pockets (> 5 mm) had highest BOP scores (89%) 
and the positive percentage of these sites decreased after SRP to 42% (IV). 
 
When percentages of all positive BOP scores per group of sites during the maintenance phase 
(V) were calculated, percentages in S and NS sites with unstable character (progressing S and 
NS sites and high-responder S sites) were higher than in stable S and NS sites or in low-
responder S sites. Positive BOP percentages were at a similar level in stable S and NS sites 
and low-responder S sites. BOP positive percentages in S sites with unstable character 
(progressing and high-responder S sites) were slightly higher than in progressing NS sites 
(V). 
 
8.4. PD AND AL VALUES 
 
PD values and GCF MMP-8 concentrations reduced significantly after SRP in studies I, III, 
IV and VI and in non-smokers’ sites in study V. S sites’ PD reduction as well as reduction of 
MMP-8 level after SRP was not statistically significant (V). S sites’ and NS sites’ initial PD 
was at the same level at the baseline (V). During the maintenance phase (V) PD levels of S 
sites remained higher than in NS sites. 
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In study III pocket reduction could still be observed at the three month maintenance visit and 
GCF MMP-8 levels were reduced by 50% compared with the post SRP situation. 
 
AL decreased after SRP statistically significantly in sites with deep pockets (> 5 mm) (IV) 
and in the longitudinal maintenance study (V) when all sites (n = 123) were examined as one 
group. AL change was not statistically significant after treatment (SRP) in study III. During 
the 12-month follow-up period AL values did not differ statistically significantly between S 
and NS sites (V). 
 
At all maintenance phase visits high-responder S sites’ pockets were deeper than in the low-
responder S sites. Baseline AL values were at similar levels in both high-responder and low-
responder S sites, but the response of AL to SRP was statistically significant only in low-
responder S sites. 
 
8.5. ELASTASE IN GCF (I) 
 
Total activities of elastase in GCF correlated significantly with GCF MMP-8 amounts. Also 
correlations with GI and BI before and after treatment, with PD before treatment and with PI 
after treatment were observed. However, when GCF elastase was measured as concentrations 
no correlations with clinical indices could be observed. 
 
8.6. CHLAMYDIA PNEUMONIAE IN PERIODONTAL LESIONS (VI) 
 
One patient was positive for C. pneumoniae in pooled subgingival plaque samples before 
periodontal treatment by SRP. The count in this patient’s sample was negative after SRP. 
This patient did not differ from the other patients when quantitative results relating to other 




To find a predictive biomarker with regard to progression of periodontal disease has been 
among the most desired ambition of biomarker researchers in periodontology. However, this 
purpose has revealed to be rather laborious and difficult. Optimally the biomarker should be 
able to differentiate ongoing connective tissue breakdown from inflammation of periodontal 
tissues. An ideal and predictive biomarker should be detected before the event of tissue 
breakdown, and it should remain at the site long enough so that it could be captured for 
analysis or for clinical testing. The most ideal situation would be that we should know the 
timescale from biomarker release to irreversible tissue damage. Besides, it should be possible 
to develop an easy to use chair-side test for clinical use based on its detection. For example, 
neutrophil elastase activity in periodontitis-affected GCF has been found to correlate with the 
clinical periodontal parameters but the correlation is not good when elastase is measured as 
concentrations (I) (Armitage et al. 1994; Murray et al. 1995). GCF collagenase activity test 
targets multiple collagenolytic MMPs (Kähäri and Saarialho-Kere 1999; Sorsa et al. 2004a; 
Ala-aho and Kähäri 2005) and for chair-side use it is inconvenient (Romanelli et al. 1999) 
when compared with an enzyme/MMP specific immunoassay which has been developed for 
the detection of MMP-8 (I, II). 
 
Most biomarkers have been studied in a cross-sectional setting or in treatment studies. The 
results from follow-up studies are available for some biomarkers (for example AST 
Chambers et al. 1991, Persson et al. 1990, Oringer et al. 2001; IgA Grbic et al. 1999, 
cytokines Il-1α, Il-1β, Il-1ra Holmlund et al. 2004; β-G Lamster et al. 1995; dipeptidyl 
peptidases II and IV Eley and Cox 1995; elastase Palcanis et al. 1992, Armitage et al. 
1994; proteases Bader and Boyd 1999; collagenase Lee et al. 1995a, Mancini et al. 1999; 
lysosomal enzymes Lamster et al. 1988; combination of markers Nakashima et al. 1996). 
In follow-up studies a major question of concern is which clinical periodontal surrogate 
parameter used in the clinic is a real or the best possible indicator of active periodontitis – a 
“golden standard” parameter for the progressing periodontitis which is not unambiguous. 
Manual periodontal probing has a relatively high measurement error. Thus, a 2—3 mm 
change in the clinical attachment level has been a demand for a confirmed progression of 
attachment loss (Page and DeRouen 1992; Armitage et al. 1994). However, the methods for 
assessing the progression of periodontitis do not agree well in identifying active sites with a 
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manual probe, automated probe nor by subtraction radiographic analysis, and a higher 
percentage of active sites can be detected with the manual probe than with the automated 
probe mostly because it is easier to manipulate the manual probe past the calculus retentions 
(Armitage et al. 1994). It has also been criticized that attachment loss as the parameter used 
to identify deteriorating sites is crude and relatively insensitive (Persson et al. 1995). The 
demand for 2—3 mm increase in attachment loss is an enormous amount of periodontal 
destruction and identifies only a small proportion of sites with progressing attachment loss. 
Therefore we used in our study also repeatedly elevated concentrations of GCF MMP-8 to 
identify sites of an unstable nature with possible minor attachment loss changes (V). Persson 
et al. (1995) proposed that a clinical trial comparing test outcome to active sites detected by 
attachment loss ≥ 2 mm would show a large proportion of apparently false positive results for 
sites which were categorised as stable because of the attachment loss less than 2 mm but 
which actually were active. 
 
Evaluation of the prognostic value of a test is both practically and statistically very 
demanding. Complicated statistical methods and evaluations have not led to definitive 
conclusions about the predictive value of the studied biomarkers (Armitage et al. 1994; Eley 
and Cox 1995; Lamster et al. 1995; Persson et al. 1995; Bader and Boyd 1999; Oringer et al. 
2001; Holmlund et al. 2004). 
 
It is possible that different types of periodontitis release elevated levels of different 
biomarkers. Also, smoking is known to have a significant effect on GCF biomarker content. 
Regarding the enzymes in GCF, smoking affects the levels of MMP-8 and neutrophil elastase 
activity (Söder 1999). More than on enzymes, smoking seems to have effect on GCF 
inflammatory and immune markers (Boström et al 1998a, b, 2000; Söder 1999; 
Giannopoulou et al. 2003b; Goutoudi et al. 2004). 
 
9.1. MMP-8 IN GINGIVAL CREVICULAR FLUID 
 
MMP-8 is the major collagenase in chronic periodontitis patients’ GCF (Sorsa et al. 1988, 
1990, 2004a, b; McCulloch 1994a, b; Pozo et al. 2005) and its concentration, activity and 
degree of activation in GCF decreases significantly with meticulous hygiene phase 
periodontal treatment (Lee et al. 1995a; Kiili et al. 2002; Figueredo et al. 2004). This could 
be confirmed also in our study; the MMP-8 concentration correlated especially with the 
 76
depth of the periodontal pocket in bleeding sites (IV). This may in fact support the value of 
MMP-8 as an indicator of progressive periodontitis with advancing attachment loss instead of 
the inflammatory state. MMP-8, as all MMPs, has normal physiologic functions for example 
in wound healing and in connective tissue turn-over. In this regard, MMP-8 has recently been 
shown to exert protective anti-inflammatory effects in LPS-induced lung inflammation and 
allergen-induced granulocytic airway inflammation due to regulation of inflammatory cell 
apoptosis (Owen et al. 2004; Gueders et al. 2005). The decrease of GCF MMP-8 
concentration during the three month maintenance phase even from the post SRP values (III) 
seemingly reflected participation of MMP-8 in periodontal tissue wound healing or defence 
reactions. The molecular forms/species of MMP-8 detected in periodontitis affected GCF 
correspond well with those detected in body’s other inflammatory exudates such as 
bronchoalveolar lavage (Prikk et al. 2001, 2002), cerebrospinal fluid from young meningitis 
patients (Lindberg et al. 2006), tracheal aspirate (Cederqvist et al. 2003), sinus mucus 
samples (Kostamo et al. 2005), tear fluid (Holopainen et al. 2003; Määttä et al. 2006), 
aqueous humor from glaucoma patients (Määttä et al. 2005, 2006b), peri-implant sulcular 
fluid (Kivelä-Rajamäki et al. 2003a, b), and can represent as well, both pro-inflammatory or 
anti-inflammatory MMP-8 species (Owen et al. 2004; Sorsa et al. 2004a; Gueders et al. 
2005). 
 
The effect of smoking on GCF MMP-8 levels seems to be twofold. In our study MMP-8 
levels tended to be lower in smokers’ GCF when compared with non-smokers’ GCF but only 
when all smokers’ sites were examined as one group. The tendency to lower MMP-8 
concentrations in smokers’ GCF compared to non-smokers has also been observed by 
Persson et al. (2003) as well as lower salivary levels of MMP-8 in current smokers by Liede 
et al. (1999). However, in smokers’ sites with progressing attachment loss during the 
maintenance phase MMP-8 concentrations were at the same level as in non-smokers’ 
progressing sites. Moreover, when sites were explored in respect to repeatedly clearly 
elevated MMP-8 concentrations during the maintenance phase, in a fraction of smokers’ sites 
MMP-8 concentrations reached the highest levels. In this group of smokers’ sites GCF 
MMP-8 concentrations reached values over 10 000 µg/l while in non-smokers’ sites the level 
of 5000 µg/l was seldom reached even in the group of sites which were considered as 
progressing (V). Thus, a lower level of MMP-8 in smokers’ GCF does not apply to all 
smokers’ sites or all smoking periodontitis patients. 
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Cigarette smoking aggravates various inflammatory tissue-destructive conditions (Bartecchi 
et al. 1994), among them periodontitis. Periodontitis with poor treatment response and 
outcome, i.e. refractory periodontitis, is more usual among smokers than non-smokers 
(MacFarlane et al. 1992; Magnusson et al. 1995; Magnusson and Walker 1996). Söder 
(1999) has detected a positive correlation between pocket probing depths and levels of 
MMP-8 in patients with refractory periodontal disease. Smokers with persistent periodontitis 
seem to have impaired granulocyte function with excessive release of protease enzymes 
(Söder et al. 2002). Smoking may interfere with the levels of protease inhibitors α2-MG and 
α1-AT which may be one mechanism by which smoking can affect the inflammatory process 
(Persson et al. 2001). Lowered neutrophil transcript levels in smokers were observed by 
Morozumi et al. (2004) which can be an indication of impaired neutrophils as a consequence 
of smoking. Petropuolos et al. (2004) studied IL-1α levels and the number of neutrophils in 
smokers’ and non-smokers’ GCF. No association between these two markers could be found 
between smokers and non-smokers either analysed by site or by patient. They concluded that 
smoking has no effect on neutrophil chemotaxis in the periodontium, and they further 
concluded that smoking may have specific actions on the inflammatory process but does not 
have a general inflammation suppressing effect. Gustafsson et al. (2000) observed that 
smokers’ circulating neutrophils are more activated than non-smokers’. The increased 
membrane expression of receptor molecules in smokers’ neutrophils indicates up-regulated 
functions, such as adhesion and degranulation. These findings support the hypothesis that the 
neutrophils from periodontitis patients who smoked may be the same in numbers than in non-
smokers but hyper-reactive (Gustafsson et al. 2000). This is a possible explanation for 
excessive MMP-8 concentrations in some smokers’ GCF (V). A two-fold increase in MMP-8 
levels has recently been found from skin of smokers compared to non-smokers (Knuutinen et 
al. 2002). Our study indicated that more than two-fold higher levels of MMP-8 in smokers’ 
GCF can be found when compared to non-smokers’ GCF. This finding differs from the 
earlier observations about smokers’ general lower GCF MMP-8 levels (Persson et al. 2003). 
 
9.2. MMP-8 SPECIFIC CHAIR-SIDE TEST 
 
Among those smokers who responded to periodontal treatment, GCF MMP-8 levels stayed at 
a lower level during the maintenance phase compared to non-smokers (V). However, a worse 
treatment response to SRP in smokers when compared with non-smokers was obvious in all 
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studied groups of sites. Smokers’ sites with stable characteristics exhibited low prevalent 
GCF MMP-8 concentrations while progressing smokers’ sites and high-responder smokers’ 
sites exhibited even clearly elevated concentrations. Thus, an elevated MMP-8 level in a 
smoker’s site is an indicator of instability and can be conveniently detected with the MMP-8 
specific chair-side test (V). Among non-smokers the finding was not as clear, possibly as 
consequence of the low number of progressing sites, better treatment response, easy 
maintenance and to relatively low cut-off value (1000 µg/l) of the test (V). 
 
The baseline sensitivity and specificity of the MMP-8 specific chair-side test related to 
clinical diagnosis was excellent: both sensitivity and specificity were very good when MMP-
8 concentrations were compared with test positive results from periodontally healthy and 
gingivitis and periodontitis subjects (IV). However, sensitivity calculated during the 
maintenance phase would have been low for progressing smokers’ and non-smokers’ sites 
(V). This is a problem which arises from the nature of periodontitis as well as from the 
definition of a progressing site in our study: sites which are categorised as progressing are 
not all in a state of disease progression at the moment of GCF sampling. As well, sites that do 
not fill the criteria of a progressing site are categorised as stable though active disease phases 
in these sites may be going on. Disease progression is episodic, occurs only infrequently and 
is slow in most chronic periodontitis patients. During a study period it is likely that only a 
small number of sites with attachment loss can be confirmed (Chambers et al. 1991). In 
addition, only a small group of periodontitis patients manifest multiple progressing sites 
(Persson et al. 1995). The nature of chronic periodontitis is that “sick” sites are not sick all 
the time. Part of the sites may be in quiescence at the particular moment. This makes the 
calculation of sensitivity difficult and gives a reason to conclude that repeatedly positive test 
results seemingly indicate sites at risk of disease progression. Sensitivity was rather poor 
when it was calculated for sites regarded as refractory (high-responder) sites and stable (low-
responder) sites (V) though refractory sites are possibly in a more constant state of instability 
and chronically “sick” which are well reflected in MMP-8 GCF concentrations (V). 
 
Repeatedly positive test results in non-smokers’ sites during the maintenance phase may also 
indicate a site at risk. However, the cut-off value of our test, 1000 µg/l of MMP-8, may be 
too low to be valuable in non-smokers. In non-smokers’ sites MMP-8 concentrations 
remained in most cases after SRP, above the concentration of the cut-off value of the test. For 
non-smokers’ a new cut-off value should be defined. With the current cut-off value the test 
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seems to be useful in smokers’ sites and it recognises both sites at risk of attachment loss 
progression and sites/patients suffering of refractory periodontitis. 
 
Moreover, with regards to the different levels of MMP-8 concentrations in GCF from healthy 
or gingivitis subjects and those with periodontitis (IV), the current cut-off value of the test 
stick may be useful in differentiating incipient periodontitis or gingivitis at risk to proceed to 
periodontitis. Hanioka et al. (2005) studied in a cross-sectional setting different combinations 
of periodontal biomarkers which could predict periodontitis, i.e. which could find persons 
with minor periodontitis changes. None of the studied biomarkers alone (haemoglobin, 
albumin, transferring, α1-AT, fibronectin, IgA, IgG, IgM, lactoferrin, myeloperoxidase, 
neutrophil elastase) in GCF was able to identify subjects with periodontal changes but GCF 
neutrophil elastase and IgA in combination seemed to afford prediction of periodontal 
disease. Thus, it cannot be excluded that the best predictor of progression of periodontitis 
will be a combination of biomarkers. 
 
Our MMP-8 chair-side dipstick test and the antibody used in IFMA are not completely 
selective or specific for the active form of MMP-8 (II); it detects also to some extent the 
latent forms of MMP-8 (Hanemaaijer et al. 1997). A MMP-8 dipstick test for monitoring 
periodontal stability could be more useful if it were supplied with a MMP-8 antibody being 
selective and specific for the active form of MMP-8. Especially the elevation of the active 
form of MMP-8 in GCF has been shown to be associated with both conversion of gingivitis 
to periodontitis and the progression of periodontitis (Lee et al. 1995a, b; Mancini et al. 1999; 
Romanelli et al.1999; Pozo et al. 2005). Nonetheless, since MMP-8 (as well as other MMPs) 
are not anymore solely regarded as tissue destructive proteinases but also anti-inflammatory 
modifiers of host and immunoresponses (Sorsa et al. 2004a, b) their levels and assessment 
from GCF (II, IV, V) may not be interpreted to indicate tissue destruction alone but also 
protective inflammation/immune responses (Owen et al. 2004; Sorsa et al. 2004a; Gueders et 
al. 2005). Future studies are required to address these aspects. Our dip-stick can be modified 
to detect also other biomarkers with known monoclonal antibodies. Thus the value of 
simultaneous detection of several biomarkers by means of more than one specific dip-stick 
should be considered. 
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9.3. CHLAMYDIA PNEUMONIAE IN PERIODONTAL LESIONS (VI) 
 
The detection method for C. pneumoniae which was used in our study is very sensitive and 
has been among the best in international comparison of PCR methods (Rintamäki et al. 
2002). The sensitivities of PCR methods for C. pneumoniae seem to vary hugely (Boman et 
al. 1999; Apfalter et al. 2002). 
 
C. pneumoniae cannot be regarded as periodontopathogen and, this far, it has not been 
identified from the oral cavity. The C. pneumoniae positive patient of our study did not differ 
with regard to periodontal parameters or GCF MMP-8 concentrations from other study 
subjects, and the positive count turned negative after SRP treatment. Nevertheless, our 
finding suggests that severe periodontal lesions can harbour C. pneumoniae (VI). Deep 
periodontal pockets may serve as a reservoir for pathogens which are not regarded as 
participating in the pathogenesis of periodontitis or other oral diseases but which have 
relevance with the systemic health status. The finding may have relevance because of the 
association of dental infections and atherosclerosis. Oral inflammation may promote the 
formation of atherosclerosis and thrombosis by elevation of blood levels of fibrinogen, 
leukocytes, clotting factors, and cytokines, and by alteration of the metabolism and functions 
of endothelial cells and monocytes/macrophages. Low-grade infections may be one cause 
behind the inflammatory reaction observed in atherosclerotic lesions and acute ischemic 
symptoms (Mattila et al. 1998). The potential role of the oral cavity as a reservoir of C. 
pneumoniae should be repeated with a large number of periodontitis patients and to be 




1. The immunoassay for MMP-8 is a specific and convenient method for chair-side GCF 
enzyme analysis in respect to the functional enzyme assays which at present are not 
specific for individual MMPs. 
2. MMP-8 levels in GCF in untreated periodontitis patients decrease with scaling and 
root planning (SRP) and are associated with improvement in clinical periodontal 
parameters. During successful maintenance MMP-8 concentrations can even further 
reduce until the wound healing phase of periodontal tissues is over. 
3. GCF concentration of MMP-8 and MMP-8 specific chair-side dipstick test may be 
useful for monitoring the treatment (SRP) response of periodontitis. 
4. GCF MMP-8 concentrations and MMP-8 testing differentiates periodontally healthy 
subjects, subjects with gingivitis and subjects with periodontitis. 
5. Despite on average lower MMP-8 levels in smokers’ GCF, MMP-8 concentrations in 
smokers’ deteriorating sites are at a similar level as in non-smokers’ corresponding 
sites. The highest GCF MMP-8 levels can be found from GCF of smokers with poor 
treatment response to conventional periodontal treatment (SRP) and instability during 
the maintenance phase. 
6. In non-smokers, pre-treatment (baseline) GCF MMP-8 concentrations decrease after 
treatment but remain higher than in healthy individuals’ or in gingivitis patients’ 
GCF. 
7. A repeatedly positive MMP-8 test result recognises periodontitis patients with a poor 
treatment response, i.e. refractory periodontitis, and sites at risk of progression of 
periodontal attachment loss especially in smokers. For non-smokers the cut-off value 
of the chair-side test stick (1000 µg/l) should be further adjusted. 
8. Gingivitis patients with repeatedly positive MMP-8 test results may be those who are 
at risk of periodontitis or are possibly already undergoing irreversible minor changes. 
9. In the future a corresponding MMP-8 dip-stick test for monitoring periodontal 
stability should be supplied with a MMP-8 antibody selective and specific for the 
active forms of MMP-8. 
10. Chlamydia pneumoniae can harbour subgingival plaque of a periodontal lesion 
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